{
 "method": [
  {
   "value": "540",
   "label": "drug CGMP warning letters, 22 January 2021 to 10 November 2026"
  },
  {
   "value": "224",
   "label": "letters about lab records, each failure quoted by a model"
  },
  {
   "value": "324 of 324",
   "label": "quotes on these cards found word for word in the letter"
  },
  {
   "value": "154",
   "label": "letters with at least one of these gaps; a letter can sit in several rows"
  }
 ],
 "hint": "Open a kind of gap to see the letters behind its count. The highlight marks FDA's words about what the record lacked.",
 "rows": [
  {
   "id": "oos-set-aside",
   "label": "A failing result set aside without a real investigation",
   "count": 67,
   "records": [
    {
     "title": "Intas Pharmaceuticals",
     "meta": [
      "28 July 2023",
      "21 CFR 211.22"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "You invalidated multiple out-of-specification (OOS) results for (b)(4) USP without adequate scientific justification.",
       "mark": [
        0,
        117
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/intas-pharmaceuticals-limited-652067-07282023",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Ava",
     "meta": [
      "14 April 2026",
      "21 CFR 211.192"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your QU failed to perform investigations into OOS results obtained during trial injections.",
       "mark": [
        0,
        91
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/ava-inc-721180-04142026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Ultra Seal",
     "meta": [
      "14 March 2022",
      "21 CFR 211.192"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "A fter obtaining passing results, you concluded that 60% ± 5% humidity storage condition was the cause for the aspirin sub-potency and (b)(4) impurities without scientific justification, maintaining that the OOS results \"may not represent condition of typical lot 18J024 consumer goods in the marketplace.\" At the time, your firm took no market action.",
       "mark": [
        34,
        185
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/ultra-seal-corporation-624650-03142022",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Medgel",
     "meta": [
      "20 July 2023",
      "21 CFR 211.192"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your investigations into bulk drug product assay out-of-specification (OOS) test results for batches (b)(4) were inadequate, as they lacked adequate hypothesis testing and evidence to support the root cause.",
       "mark": [
        0,
        207
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/medgel-private-limited-654085-07202023",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Natural Essentials",
     "meta": [
      "10 November 2026",
      "21 CFR 211.192"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "Nevertheless, you released the affected lots based on passing retest results, invalidating the original failing results without scientific justification.",
       "mark": [
        0,
        153
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/natural-essentials-inc-738543-11102026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "USV",
     "meta": [
      "2 November 2026",
      "21 CFR 211.160(b)"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your visual inspection procedure requires the investigation of atypical trends, yet you failed to investigate atypical trends in (b)(4) injection batch (b)(4) .",
       "mark": [
        0,
        160
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/usv-private-limited-735938-11022026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Rohto Pharmaceutical",
     "meta": [
      "14 October 2026",
      "21 CFR 211.192"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "Rather than conducting a full 100% re-inspection, only (b)(4) units per batch were re-inspected, and the investigations did not characterize the nature, composition, or source of the particles.",
       "mark": [
        0,
        193
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/rohto-pharmaceutical-co-ltd-733215-10142026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Baxter International",
     "meta": [
      "29 September 2026",
      "21 CFR 211.192"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "You invalidated the sterility result without adequate scientific justification and released this lot in July 2025.",
       "mark": [
        0,
        114
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/baxter-international-inc-733231-09292026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "SnugZ USA",
     "meta": [
      "28 September 2026",
      "21 CFR 211.192"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm retested failing samples or prepared and tested new samples without justification until your analysts obtained passing results.",
       "mark": [
        0,
        137
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/snugz-usa-inc-735284-09282026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Happy Farm Botanicals",
     "meta": [
      "1 September 2026",
      "21 CFR 211.166(a)"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "Multiple timepoints within your a ccelerated stability study were reported as \"Not Available\" and you identified failing results at (b)(4) for viscosity, which you did not investigate.",
       "mark": [
        98,
        184
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/happy-farm-botanicals-inc-731926-09012026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Auriga Research",
     "meta": [
      "12 August 2026",
      "21 CFR 211.22(d)"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "Concerning an OOS investigation for assay of (b)(4) after failing the initial test, hypothesis, and five repeat tests, you invalidated all these results.",
       "mark": [
        0,
        153
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/auriga-research-pvt-ltd-730694-08122026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Spa De Soleil",
     "meta": [
      "8 July 2026",
      "21 CFR 211.192"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "You resampled and retested the (b)(4) for microbiological quality to obtain passing results and continued to use the (b)(4) .",
       "mark": [
        0,
        125
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/spa-de-soleil-inc-728508-07082026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Huons",
     "meta": [
      "15 June 2026",
      "21 CFR 211.192"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm still used the passing hypothesis test results as justification to invalidate the original test result.",
       "mark": [
        0,
        113
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/huons-co-ltd-724650-06152026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Gopaldas Visram",
     "meta": [
      "2 June 2026",
      "21 CFR 211.192"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "Furthermore, our review indicates that your QU failed to investigate data discrepancies associated with identification testing for talc.",
       "mark": [
        13,
        136
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/gopaldas-visram-co-ltd-721755-06022026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Pharmathen International",
     "meta": [
      "27 May 2026",
      "21 CFR 211.192"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm also failed to investigate failures to meet in-process acceptance criteria for visible particulates.",
       "mark": [
        0,
        110
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/pharmathen-international-sa-723680-05272026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "ProRx",
     "meta": [
      "7 April 2026",
      "21 CFR 211.192"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm's responses did not include any retroactive investigation or root cause analysis addressing the multiple microbial growth detected in personnel fingertip samples collected following production activities in the ISO 5 area.",
       "mark": [
        0,
        232
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/prorx-llc-723704-04072026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Intas Pharmaceuticals",
     "meta": [
      "30 March 2026",
      "21 CFR 211.192"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "For example, you invalidated an assay result of (b)(4) % for a sample batch ( (b)(4) ) used as a control due to \"solution preparation error\" without conclusive supporting evidence, despite the sample preparation analysis being deemed \"satisfactory\" during the laboratory Phase I investigation.",
       "mark": [
        13,
        179
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/intas-pharmaceuticals-limited-721151-03302026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "RC Outsourcing",
     "meta": [
      "20 March 2026",
      "21 CFR 211.192"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "We acknowledge the actions taken by your firm in response to your failure to investigate numerous instances of microbial recovery from the sleeves of gowns worn by operators who enter the ISO 5 space during sterile drug production.",
       "mark": [
        61,
        231
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/rc-outsourcing-llc-722877-03202026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Microbiological Testing & Consulting",
     "meta": [
      "16 March 2026",
      "21 CFR 211.22"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "However, records collected during an FDA inspection of one of your customers (b)(4) , indicated that your firm reported several OOL for TAMC and objectionable microorganism results within the past two years.",
       "mark": [
        9,
        207
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/microbiological-testing-consulting-llc-720374-03162026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Tentamus India",
     "meta": [
      "3 March 2026",
      "21 CFR 211.192"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "You had no investigation or supporting documentation available to justify the change from the original TNTC result to the revised < (b)(4) cfu/g result.",
       "mark": [
        0,
        152
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/tentamus-india-private-limited-720463-03032026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Tower Laboratories",
     "meta": [
      "23 December 2025",
      "21 CFR 211.192"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your laboratory investigations did not include sufficient details and lacked root causes for the failures.",
       "mark": [
        0,
        106
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/tower-laboratories-ltd-717456-12232025",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Unipack",
     "meta": [
      "19 December 2025",
      "21 CFR 211.192"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "However, your investigation lacked scientific justification to invalidate the OOS result and ultimately release the batch.",
       "mark": [
        0,
        122
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/unipack-llc-716621-12192025",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Siddha Flower Essences",
     "meta": [
      "4 November 2025",
      "21 CFR 211.192"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "You failed to adequately investigate finished drug product sample results that were out of limit (OOL) for microbiological contamination.",
       "mark": [
        0,
        137
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/siddha-flower-essences-llc-dba-siddha-remedies-713217-11042025",
     "urlLabel": "Read the letter"
    },
    {
     "title": "DermaRite Industries",
     "meta": [
      "27 October 2025",
      "21 CFR 211.192"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "Despite this retest also producing failing results, your firm released the batch for distribution.",
       "mark": [
        0,
        98
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/dermarite-industries-llc-710997-10272025",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Creative Essences",
     "meta": [
      "25 September 2025",
      "21 CFR 211.192"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your QU failed to adequately investigate multiple microbial OOS results from your (b)(4) water system which is used as a component in your drug products.",
       "mark": [
        0,
        153
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/creative-essences-inc-710658-09252025",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Persōn & Covey",
     "meta": [
      "23 September 2025",
      "21 CFR 211.22"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "The initial (b)(4) test results were disregarded and not investigated by your QU.",
       "mark": [
        0,
        81
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/person-covey-inc-711191-09232025",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Wisconsin Pharmacal Company",
     "meta": [
      "22 August 2025",
      "21 CFR 211.192"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "You released the referenced batch for commercial distribution based on a passing retest result obtained without conducting a thorough investigation into the root cause of the contamination.",
       "mark": [
        0,
        189
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/wisconsin-pharmacal-company-llc-710329-08222025",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Shiva Analyticals",
     "meta": [
      "23 July 2025",
      "21 CFR 211.192"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "New test results were used as the basis for invalidating OOS results without also performing an adequate root cause investigation.",
       "mark": [
        0,
        130
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/shiva-analyticals-private-limited-707857-07232025",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Oasis Medical",
     "meta": [
      "15 July 2025",
      "21 CFR 211.192"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "You concluded in NCR 24014 that, because the contaminant was found only on the syringe and cap and not the contents of the syringe, the likely root cause of the sterility failure was laboratory contamination due to excessive handling during the test.",
       "mark": [
        0,
        250
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/oasis-medical-inc-707198-07152025",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Exela Pharma Sciences",
     "meta": [
      "2 July 2025"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "However, two tests of lot (b)(4) were invalidated and the third test was passed without scientific rationale.",
       "mark": [
        0,
        109
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/exela-pharma-sciences-llc-709859-07022025",
     "urlLabel": "Read the letter"
    },
    {
     "title": "CTK OTC Laboratories",
     "meta": [
      "19 May 2025",
      "21 CFR 211.192"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "You then adjusted the potency by adding additional APIs and re-mixing the batch.",
       "mark": [
        0,
        80
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/ctk-otc-laboratories-llc-formerly-fmk-labs-inc-705479-05192025",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Evi Labs",
     "meta": [
      "14 May 2025",
      "21 CFR 211.192"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "Ensure thorough investigations into unexplained discrepancies or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).",
       "mark": [
        0,
        197
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/evi-labs-llc-705846-05142025",
     "urlLabel": "Read the letter"
    },
    {
     "title": "NWL Netherlands Services",
     "meta": [
      "1 April 2025",
      "21 CFR 211.192"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "For example, you did not adequately investigate repeated out-of-limit (OOL) results for microbial content in your (b)(4) system.",
       "mark": [
        13,
        127
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/nwl-netherlands-services-bv-701206-04012025",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Viatris",
     "meta": [
      "19 December 2024",
      "21 CFR 211.192"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "You invalidated OOT assay results and during retest subsequently dismissed an anomalous content uniformity result for (b)(4) mg Capsules, batch (b)(4) , attributing the original issue to HPLC column leakage.",
       "mark": [
        0,
        207
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/viatris-inc-690897-12192024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Skye Biologics Holdings",
     "meta": [
      "16 December 2024",
      "21 CFR 211.192"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "For example, from January 2021 to August 2022, you failed to investigate three action-level excursions for environmental monitoring observed in the a septic processing area (e.g., laminar flow hoods).",
       "mark": [
        13,
        200
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/skye-biologics-holdings-llc-654466-12162024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "LCC",
     "meta": [
      "21 November 2024",
      "21 CFR 211.194(a)"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "No out-of-specification (OOS) investigation was performed.",
       "mark": [
        0,
        58
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/lcc-ltd-688576-11212024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Pinnacle Transplant Technologies",
     "meta": [
      "1 October 2024",
      "21 CFR 211.192"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "Specifically, between July 2020 and February 2022, your firm failed to investigate 8 sterility failures.",
       "mark": [
        0,
        104
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/pinnacle-transplant-technologies-llc-646783-10012024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Outin Futures",
     "meta": [
      "25 September 2024",
      "21 CFR 211.22(a) and (d)"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your QU released OTC drug product batch using retest result without conducting an investigation when the original assay test failed to meet the release specification.",
       "mark": [
        0,
        166
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/outin-futures-corp-684688-09252024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Accupack Midwest",
     "meta": [
      "15 August 2024",
      "21 CFR 211.192"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "Several failures were noted during your firm's (b)(4) testing on your water samples where your firm resampled and retested the water without an appropriate investigation (see 21 CFR 211.192).",
       "mark": [
        0,
        169
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/accupack-midwest-inc-680228-08152024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Intercos Europe",
     "meta": [
      "15 August 2024",
      "21 CFR 211.192"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "You noted the result was likely due to a sampling error, but provided no assessment of your (b)(4) system, nor any evidence of the investigation leading to your conclusion.",
       "mark": [
        0,
        172
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/intercos-europe-spa-682273-08152024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Laboratorio Magnachem International",
     "meta": [
      "18 June 2024",
      "21 CFR 211.192"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "You failed to conduct adequate investigations into out-of-specification (OOS) stability testing results and missing stability intervals for your multiple drug products.",
       "mark": [
        0,
        168
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/laboratorio-magnachem-international-673796-06182024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Westwood Laboratories",
     "meta": [
      "17 April 2024",
      "21 CFR 211.192"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "A complaint for (b)(4) , Lot (b)(4) , reporting the product was \"watery thin.\" During your investigation, you obtained an out of specification (OOS) result for viscosity from a retain sample that was not adequately investigated and documented in the complaint report.",
       "mark": [
        79,
        267
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/westwood-laboratories-llc-674728-04172024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Stokes Healthcare",
     "meta": [
      "2 April 2024"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "Invalidating original potency results based on resampling results without scientific justification.",
       "mark": [
        0,
        99
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/stokes-healthcare-inc-dba-epicur-pharma-677624-04022024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Central Admixture Pharmacy Services",
     "meta": [
      "25 March 2024"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "You do not address the practice of rounding and averaging individual out of specification results and then ultimately reporting as a passing final result.",
       "mark": [
        0,
        154
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/central-admixture-pharmacy-services-inc-675065-03252024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Fresenius Kabi",
     "meta": [
      "14 September 2023",
      "21 CFR 211.192"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "At the time of the inspection, your investigations into these excursions were not thorough because the investigations did not include an evaluation to determine the root cause, although batches had been released.",
       "mark": [
        0,
        212
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/fresenius-kabi-ag-657085-09142023",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Kimera Labs",
     "meta": [
      "1 September 2023",
      "21 CFR 211.192"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "For example, you failed to document an investigation into the positive sterility result obtained for XoGlo®Pro lot 4000078P.",
       "mark": [
        13,
        124
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/kimera-labs-inc-649343-09012023",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Fuller Industries",
     "meta": [
      "28 June 2023",
      "21 CFR 211.192"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "In addition, some PCMX assay results appeared OOS and were not investigated (21 CFR 211.192).",
       "mark": [
        13,
        75
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/fuller-industries-inc-654425-06282023",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Stratus Biosystems",
     "meta": [
      "5 June 2023",
      "21 CFR 211.192"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "While you identified the contaminating organisms, you failed to provide evidence that you investigated these failures to determine the root cause, product impact, or corrective and preventative actions.",
       "mark": [
        0,
        202
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/stratus-biosystems-llc-dba-cellgenuity-regenerative-science-631303-06052023",
     "urlLabel": "Read the letter"
    },
    {
     "title": "RenatiLabs",
     "meta": [
      "1 June 2023",
      "21 CFR 211.165(f)"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "For example: You failed to reject WJMAX™ lot REN20210205 after this lot failed sterility testing, due to contamination with Staphylococcus epidermidis , according to the final report from your contract laboratory dated March 22, 2021.",
       "mark": [
        13,
        234
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/renatilabs-inc-646353-06012023",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Zermat International",
     "meta": [
      "6 April 2023",
      "21 CFR 211.192"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "Our review also noted that lot# (b)(4) was OOS for specific gravity and no further investigation occurred.",
       "mark": [
        27,
        106
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/zermat-international-sa-de-cv-647232-04062023",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Dunagin Pharmaceuticals",
     "meta": [
      "22 February 2023",
      "21 CFR 211.22(a)"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "For example, your Quality Unit (QU) failed to initiate and document an investigation into out-of-specification (OOS) results.",
       "mark": [
        13,
        125
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/dunagin-pharmaceuticals-inc-dba-massco-dental-644335-02222023",
     "urlLabel": "Read the letter"
    },
    {
     "title": "AG Hair",
     "meta": [
      "28 November 2022",
      "21 CFR 211.192"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "You released the (b)(4) drug product without conducting a comprehensive investigation, including to document the root cause determination, and speciation and product impact assessment based on the recovered microorganisms.",
       "mark": [
        0,
        222
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/ag-hair-limited-638646-11282022",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Glenmark Pharmaceuticals",
     "meta": [
      "22 November 2022",
      "21 CFR 211.192"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "However, your response did not adequately address your firm's failure to investigate the assay failure and market impact at the time of its occurrence and it did not include an overall management strategy for improving all phases of your investigations.",
       "mark": [
        9,
        150
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/glenmark-pharmaceuticals-limited-637314-11222022",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Advanced Cosmetic Research Laboratories",
     "meta": [
      "26 September 2022",
      "21 CFR 211.22(a) and (d)"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "Out-of-specification (OOS) results for viscosity and specific gravity in bulk and finished drug product were not investigated.",
       "mark": [
        0,
        126
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/advanced-cosmetic-research-laboratories-inc-635176-09262022",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Gordon Laboratories",
     "meta": [
      "17 August 2022",
      "21 CFR 211.192"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "For example, you did not investigate multiple results above your total aerobic microbial count action limit of (b)(4) cfu/g.",
       "mark": [
        0,
        124
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/gordon-laboratories-inc-631432-08172022",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Monarch PCM",
     "meta": [
      "10 June 2022",
      "21 CFR 211.192"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "Additional examples of inadequate investigations include: Failure to thoroughly investigate multiple out-of-limit microbial results in both your old and new (b)(4) water systems.",
       "mark": [
        58,
        178
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/monarch-pcm-llc-620779-06102022",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Colorful Products",
     "meta": [
      "10 May 2022",
      "21 CFR 211.67(a)"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "In addition, you could not provide a written investigation, including a description of your resanitization activities, a root cause for the elevated microbial results, or an appropriate CAPA.",
       "mark": [
        13,
        191
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/colorful-products-corporation-624415-05102022",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Cetylite Industries",
     "meta": [
      "14 April 2022",
      "21 CFR 211.192"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "Without adequate scientific justification you again retested the sample using two additional methods (b)(4) and (b)(4) and obtained passing results.",
       "mark": [
        0,
        148
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/cetylite-industries-inc-622823-04142022",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Verde Cosmetic Labs",
     "meta": [
      "30 March 2022",
      "21 CFR 211.160(a)"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "These OOS results were not investigated.",
       "mark": [
        0,
        40
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/verde-cosmetic-labs-llc-622534-03302022",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Accu Bio-Chem Laboratories",
     "meta": [
      "24 February 2022",
      "21 CFR 211.192"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your practice of preparing and testing new samples of OTC drug products to confirm the original test results without first adequately investigating the initial failing result is not scientifically justified.",
       "mark": [
        0,
        207
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/accu-bio-chem-laboratories-619450-02242022",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Yusef Manufacturing Laboratories",
     "meta": [
      "8 February 2022",
      "21 CFR 211.192"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "Without conducting a full-scale investigation (e.g., manufacturing process), you attributed that the initial failing results to heated filling nozzles at the start of production, which is quenched when filling the first sample.",
       "mark": [
        0,
        227
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/yusef-manufacturing-laboratories-llc-621026-02082022",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Dental Technologies",
     "meta": [
      "30 November 2021",
      "21 CFR 211.192"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm invalidated failing microbiological results obtained by your third-party laboratory during stability testing of a batch of AlphaCaine topical anesthetic gel in March 2019, without scientific justification.",
       "mark": [
        0,
        215
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/dental-technologies-inc-612599-11302021",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Sanitor",
     "meta": [
      "29 November 2021",
      "21 CFR 211.22"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your quality unit (QU) failed to adequately investigate and identify the root cause for the microbial contamination in your hand sanitizer drug product.",
       "mark": [
        0,
        152
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/sanitor-corporation-616232-11292021",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Missouri Analytical Laboratories",
     "meta": [
      "30 September 2021",
      "21 CFR 211.192"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "You relied on resampling and retesting to invalidate the original OOS results without identifying a scientifically justified root cause.",
       "mark": [
        0,
        136
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/missouri-analytical-laboratories-inc-615319-09302021",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Utah Cord Bank",
     "meta": [
      "10 August 2021",
      "21 CFR 211.192"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "Specifically, from July 2017 to January 2020, you failed to thoroughly investigate 16 sterility failures.",
       "mark": [
        0,
        105
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/utah-cord-bank-llc-dba-utah-cell-bank-614013-08102021",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Sanit Technologies",
     "meta": [
      "27 July 2021",
      "21 CFR 211.192"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "Related to the release of drug products with microbiological contamination, your QU failed to execute its duties and oversight related to the following: Opening and thoroughly investigating out-of-specification results (OOS) for your finished drug products when they failed their finished product specifications for microorganisms.",
       "mark": [
        153,
        331
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/sanit-technologies-llc-dba-durisan-614278-07272021",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Allay Pharmaceuticals",
     "meta": [
      "27 January 2021",
      "21 CFR 211.192"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your investigation into the OOS sample result was inadequate and did not identify CAPA.",
       "mark": [
        0,
        87
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/allay-pharmaceuticals-llc-609023-01272021",
     "urlLabel": "Read the letter"
    }
   ],
   "note": "67 of 540 letters, newest first after the ones the post quotes"
  },
  {
   "id": "run-context",
   "label": "Sample preparation, instrument or timing not recorded",
   "count": 57,
   "records": [
    {
     "title": "Ava",
     "meta": [
      "14 April 2026",
      "21 CFR 211.194(a)"
     ],
     "tags": [
      {
       "label": "Preparation not recorded"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Furthermore, your laboratory notebook contains no record of the sample preparations associated with the OOS results.",
       "mark": [
        0,
        116
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/ava-inc-721180-04142026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Medgel",
     "meta": [
      "20 July 2023",
      "21 CFR 211.22"
     ],
     "tags": [
      {
       "label": "Not recorded at the time"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Contemporaneous documentation of laboratory data that would support batch release (e.g., you had destroyed microbiological plates before recording the data).",
       "mark": [
        0,
        157
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/medgel-private-limited-654085-07202023",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Hanlim Pharm",
     "meta": [
      "2 October 2026",
      "21 CFR 211.194(a)"
     ],
     "tags": [
      {
       "label": "Not recorded at the time"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Contemporaneous documentation of EM and personnel monitoring sampling data in laboratory records (21 CFR 211.194(a)).",
       "mark": [
        0,
        117
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/hanlim-pharm-co-ltd-734782-10022026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Baxter International",
     "meta": [
      "29 September 2026",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Not recorded at the time"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "It also fails to thoroughly address the lack of contemporaneous documentation of any subsequent deviation that could have theoretically occurred.",
       "mark": [
        0,
        145
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/baxter-international-inc-733231-09292026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Empower Clinic Services",
     "meta": [
      "18 September 2026"
     ],
     "tags": [
      {
       "label": "Not recorded at the time"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Finally, our review also noted multiple media fill records were transcribed on Form Revision 3 because the original results were documented on the wrong form.",
       "mark": [
        0,
        158
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/empower-clinic-services-llc-dba-empower-pharmacy-738238-09182026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Reliance Life Sciences",
     "meta": [
      "18 August 2026",
      "21 CFR 211.194(a)"
     ],
     "tags": [
      {
       "label": "Preparation not recorded"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "In addition, your Laboratory Information Management System (LIMS) did not include a dilution factor to calculate the number of cfus per gram or milliliter of product for microbial limit test results, as required by your own procedures and applicable compendial methods.",
       "mark": [
        13,
        198
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/reliance-life-sciences-private-limited-730801-08182026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Auriga Research",
     "meta": [
      "12 August 2026",
      "21 CFR 211.194(a)"
     ],
     "tags": [
      {
       "label": "Not recorded at the time"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "You did not accurately complete laboratory records contemporaneously at the time you performed the laboratory activities.",
       "mark": [
        0,
        121
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/auriga-research-pvt-ltd-730694-08122026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Lico Industries",
     "meta": [
      "30 July 2026",
      "21 CFR 211.22(a)"
     ],
     "tags": [
      {
       "label": "Not recorded at the time"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Specifically, your response fails to address significant data integrity lapses documented at your facility which include backdating of quality release labels, entry of temperature data when the thermometer was inoperable, and lack of batch records to document manufacturing activities for drug products.",
       "mark": [
        121,
        157
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/lico-industries-llc-dba-american-towelette-company-729921-07302026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Dabur India",
     "meta": [
      "24 July 2026",
      "21 CFR 211.194(a)"
     ],
     "tags": [
      {
       "label": "Instrument not recorded"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "You also fai led to make the required entries in your equipment logbooks to reflect the use of multiple instruments for the specific batch release tests performed.",
       "mark": [
        20,
        163
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/dabur-india-limited-728828-07242026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "BioMylz",
     "meta": [
      "13 July 2026",
      "21 CFR 211.22"
     ],
     "tags": [
      {
       "label": "Not recorded at the time"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "For example, your personnel used a pencil to initially record volume entries and subsequently overwrote them in ink after completion of the weight check activity.",
       "mark": [
        0,
        162
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/biomylz-pvt-ltd-729483-07132026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Spa De Soleil",
     "meta": [
      "8 July 2026",
      "21 CFR 211.100(a)"
     ],
     "tags": [
      {
       "label": "Instrument not recorded"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Additionally, your completed batch records did not include details pertaining to critical processing steps subject to variation (e.g., (b)(4) times, speeds) or identification of certain equipment including scales used for your weight-based manufacturing processes.",
       "mark": [
        156,
        264
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/spa-de-soleil-inc-728508-07082026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Wizcure Pharmaa",
     "meta": [
      "24 June 2026",
      "21 CFR 211.194(a)"
     ],
     "tags": [
      {
       "label": "Not recorded at the time"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Our investigators also found laboratory forms were pre-filled with microbial testing information (e.g., sterility and (b)(4) testing results), further demonstrating untrustworthy documentation.",
       "mark": [
        0,
        193
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/wizcure-pharmaa-private-limited-726378-06242026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Genzyme Ireland",
     "meta": [
      "22 June 2026",
      "21 CFR 211.194(a)"
     ],
     "tags": [
      {
       "label": "Not recorded at the time"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Additionally, logbooks documenting when environmental monitoring was performed were not always consistent with cleanroom entry and exit times for personnel performing the sampling.",
       "mark": [
        14,
        180
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/genzyme-ireland-limited-728681-06222026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Huons",
     "meta": [
      "15 June 2026",
      "21 CFR 211.194(a)"
     ],
     "tags": [
      {
       "label": "Not recorded at the time"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "However, your team leader had instructed staff to discard the bioburden plat es with significant growth and had manipulated camera timestamps to create backdated documentation.",
       "mark": [
        108,
        176
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/huons-co-ltd-724650-06152026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Pharmathen International",
     "meta": [
      "27 May 2026",
      "21 CFR 211.160(a)"
     ],
     "tags": [
      {
       "label": "Not recorded at the time"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "You also did not document the associated data and information contemporaneously.",
       "mark": [
        0,
        80
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/pharmathen-international-sa-723680-05272026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Pro Numb Tattoo Numbing Spray",
     "meta": [
      "14 April 2026",
      "21 CFR 211.68(a)"
     ],
     "tags": [
      {
       "label": "Instrument not recorded"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Establishment of routine calibration and written records of calibration checks according to a written program designed to ensure proper performance of equipment used in the manufacture, processing, packing, and holding of a drug product (21 CFR 211.68(a)).",
       "mark": [
        0,
        205
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/pro-numb-tattoo-numbing-spray-llc-722589-04142026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Microbiological Testing & Consulting",
     "meta": [
      "16 March 2026",
      "21 CFR 211.160(b)"
     ],
     "tags": [
      {
       "label": "Preparation not recorded"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "For example, you routinely failed to document specific attributes of each test such as: equipment number sample size media batch number sample dilutions incubation temperatures name/signature of performing analyst According to your personnel, your firm also lacked adequate equipment logs to track usage and maintenance.",
       "mark": [
        0,
        213
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/microbiological-testing-consulting-llc-720374-03162026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Fareva Morton Grove",
     "meta": [
      "3 March 2026",
      "21 CFR 211.194(a)"
     ],
     "tags": [
      {
       "label": "Not recorded at the time"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Specifically, you did not contemporaneously record negative results for sample plates on which no microbiological growth was observed.",
       "mark": [
        0,
        134
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/fareva-morton-grove-719408-03032026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Tentamus India",
     "meta": [
      "3 March 2026",
      "21 CFR 211.160(a)"
     ],
     "tags": [
      {
       "label": "Not recorded at the time"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Additionally, your lab manager was observed on August 14, 2025 signing and backdating spectrometry analysis reconciliation records to March 6, 2025.",
       "mark": [
        0,
        148
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/tentamus-india-private-limited-720463-03032026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "A. Nelson",
     "meta": [
      "12 February 2026",
      "21 CFR 211.22(d)"
     ],
     "tags": [
      {
       "label": "Not recorded at the time"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Notably, a handwritten sticky note indicating an \"out-of-trend\" result with a quality determination was discovered among the discarded materials, yet this deviation was neither properly documented at the time of performance nor adequately investigated.",
       "mark": [
        0,
        252
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/nelson-co-ltd-720283-02122026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Unipack",
     "meta": [
      "19 December 2025",
      "21 CFR 211.194(a)"
     ],
     "tags": [
      {
       "label": "Not recorded at the time"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Incomplete laboratory records Our investigator observed entries were not entered contemporaneously in your laboratory notebook.",
       "mark": [
        30,
        127
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/unipack-llc-716621-12192025",
     "urlLabel": "Read the letter"
    },
    {
     "title": "LiquidCapsule Manufacturing",
     "meta": [
      "19 December 2025",
      "21 CFR 211.188"
     ],
     "tags": [
      {
       "label": "Not recorded at the time"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "For example, the batch rec ord for batch (b)(4) , manufactured in December 2024, approximately 6 months before the inspection, did not contain complete information including the full results of in-process testing, and shows multiple instances where initials and dates were pre-filled without documentation of performance, or evidence of performance.",
       "mark": [
        218,
        349
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/liquidcapsule-manufacturing-llc-717069-12192025",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Persōn & Covey",
     "meta": [
      "23 September 2025",
      "21 CFR 211.22"
     ],
     "tags": [
      {
       "label": "Not recorded at the time"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "The rework conducted was not contemporaneously documented.",
       "mark": [
        0,
        58
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/person-covey-inc-711191-09232025",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Amneal Pharmaceuticals",
     "meta": [
      "27 August 2025",
      "21 CFR 211.160(b)"
     ],
     "tags": [
      {
       "label": "Not recorded at the time"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Inadequate documentation practices when recording sample results of bacterial endotoxin tests for water for injection, including non-contemporaneous documenting of negative sample results and assigning a passing result to a positive control sample prior to the actual observation and confirmation of the result.",
       "mark": [
        129,
        311
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/amneal-pharmaceuticals-llc-709894-08272025",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Health and Natural Beauty USA",
     "meta": [
      "28 July 2025",
      "21 CFR 211.194"
     ],
     "tags": [
      {
       "label": "Preparation not recorded"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your laboratory records did not include appropriate descriptions of samples, methods, solution references, or requirements for contemporaneous documentation practices.",
       "mark": [
        0,
        167
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/health-and-natural-beauty-usa-corp-700187-07282025",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Dynamic Blending Specialists",
     "meta": [
      "18 June 2025",
      "21 CFR 211.22"
     ],
     "tags": [
      {
       "label": "Not recorded at the time"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "For example: Your scale calibration logs consisted of loose pages printed without unique identifiers.",
       "mark": [
        13,
        101
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/dynamic-blending-specialists-inc-701278-06182025",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Kenil Healthcare",
     "meta": [
      "12 June 2025",
      "21 CFR 211.100(b)"
     ],
     "tags": [
      {
       "label": "Not recorded at the time"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Specifically, investigators observed your quality assurance manager generating and completing equipment qualification documents investigators previously requested.",
       "mark": [
        0,
        163
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/kenil-healthcare-private-limited-704786-06122025",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Zhejiang Huahai Pharmaceutical",
     "meta": [
      "6 June 2025"
     ],
     "tags": [
      {
       "label": "Not recorded at the time"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Data Integrity During the inspection, our investigator observed a laboratory employee who appeared to be approving environmental monitoring records non-contemporaneously (or \"backdating\").",
       "mark": [
        38,
        188
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/zhejiang-huahai-pharmaceutical-co-ltd-707145-06062025",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Yangzhou Sion Commodity",
     "meta": [
      "12 March 2025",
      "21 CFR 211.194(a)"
     ],
     "tags": [
      {
       "label": "Preparation not recorded"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "During our inspection, you confirmed that original data, including balance printout slips, (b)(4) times, (b)(4) , sample preparations, and equipment logs were not maintained.",
       "mark": [
        0,
        174
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/yangzhou-sion-commodity-co-ltd-699183-03122025",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Skye Biologics Holdings",
     "meta": [
      "16 December 2024",
      "21 CFR 211.188(b)"
     ],
     "tags": [
      {
       "label": "Preparation not recorded"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "The weight of, for e.g., umbilical cord tissue used in processing. b. The amount of saline used to formulate the final product.",
       "mark": [
        0,
        127
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/skye-biologics-holdings-llc-654466-12162024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "LCC",
     "meta": [
      "21 November 2024",
      "21 CFR 211.194(a)"
     ],
     "tags": [
      {
       "label": "Not recorded at the time"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "A review of the discarded pH test records found discrepancies between the test dates, pH calibration data, and the final test report.",
       "mark": [
        0,
        133
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/lcc-ltd-688576-11212024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Unexo Lifesciences",
     "meta": [
      "6 November 2024",
      "21 CFR 211.188"
     ],
     "tags": [
      {
       "label": "Not recorded at the time"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your executive management admitted to not having all the batch records for the released drug products and batch production records were \"retrospectively prepared\" to provide to the investigators.",
       "mark": [
        0,
        195
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/unexo-lifesciences-private-limited-688163-11062024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Analytical Food Laboratories",
     "meta": [
      "10 October 2024",
      "21 CFR 211.22"
     ],
     "tags": [
      {
       "label": "Preparation not recorded"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "For example, your QU failed to adequately: control the issuance and reconciliation of uncontrolled loose forms used for documenting laboratory testing, equipment uses, and calibrations. review laboratory records to ensure completeness, including documentation of blank, sample, and mobile phase preparations.",
       "mark": [
        186,
        308
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/analytical-food-laboratories-inc-687513-10102024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "MMC Healthcare",
     "meta": [
      "24 September 2024",
      "21 CFR 211.22(a)"
     ],
     "tags": [
      {
       "label": "Not recorded at the time"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "During the inspection of your facility our Investigator observed that your 2021 (b)(4) Tablets \"PROCESS VALIDATION\" report had data added, backdated signatures, and replaced pages.",
       "mark": [
        70,
        180
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/mmc-healthcare-ltd-684644-09242024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Eugia Pharma Specialities",
     "meta": [
      "15 August 2024",
      "21 CFR 211.194(a)"
     ],
     "tags": [
      {
       "label": "Not recorded at the time"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your operators used non-viable particle counts from a different time and place and altered the time to correspond to the desired results in the batch record.",
       "mark": [
        0,
        157
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/eugia-pharma-specialities-limited-681905-08152024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Intercos Europe",
     "meta": [
      "15 August 2024",
      "21 CFR 211.194(a)"
     ],
     "tags": [
      {
       "label": "Preparation not recorded"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "However, solvent information, including lot numbers and quantities, was not documented.",
       "mark": [
        0,
        87
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/intercos-europe-spa-682273-08152024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Greco Gas",
     "meta": [
      "12 August 2024",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Not recorded at the time"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Additionally, you lacked investigations into the following instances where your employees failed to record manufacturing and testing data during the production of medical gases concurrent with their performance.",
       "mark": [
        14,
        211
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/greco-gas-inc-683090-08122024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Jiangsu Hengrui Pharmaceuticals",
     "meta": [
      "11 July 2024",
      "21 CFR 211.22"
     ],
     "tags": [
      {
       "label": "Not recorded at the time"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your production manager repeatedly accessed and printed uncontrolled blank copies of production records, media fill records, visual inspection records, process validation batch records, and cleaning validation records saved on his computer or through your document management system.",
       "mark": [
        0,
        184
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/jiangsu-hengrui-pharmaceuticals-co-ltd-679790-07112024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Central Admixture Pharmacy Services",
     "meta": [
      "10 July 2024",
      "21 CFR 211.160(a)"
     ],
     "tags": [
      {
       "label": "Not recorded at the time"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to document at the time of performance required laboratory control mechanisms (21 CFR 211.160(a)). 7.",
       "mark": [
        0,
        94
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/central-admixture-pharmacy-services-inc-687936-07102024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "FirstCham",
     "meta": [
      "3 April 2024",
      "21 CFR 211.22"
     ],
     "tags": [
      {
       "label": "Not recorded at the time"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "In addition, you approved an inadequate stability study and failed to ensure reliability of data relating to drug product quality (e.g., prefilled documents, deleted chromatographic data, inadequate investigations, etc.).",
       "mark": [
        0,
        221
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/firstcham-co-ltd-672903-04032024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Stokes Healthcare",
     "meta": [
      "2 April 2024"
     ],
     "tags": [
      {
       "label": "Instrument not recorded"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Did not record chromatography column temperature information for specificity, limit of quantification, limit of detection, linearity, accuracy, precision, intermediate precision, and stability testing; d.",
       "mark": [
        0,
        201
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/stokes-healthcare-inc-dba-epicur-pharma-677624-04022024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Kilitch Healthcare India",
     "meta": [
      "28 March 2024",
      "21 CFR 211.194(a)"
     ],
     "tags": [
      {
       "label": "Not recorded at the time"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Batch record information for environmental monitoring (EM) is not recorded at the time of completion.",
       "mark": [
        0,
        101
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/kilitch-healthcare-india-limited-672956-03282024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Thai Nakorn Patana",
     "meta": [
      "27 February 2024",
      "21 CFR 211.194(a)"
     ],
     "tags": [
      {
       "label": "Preparation not recorded"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Complete data derived from standard preparation, sample preparation, and assay testing of your drug products was properly documented and retained (21 CFR 211.194(a)).",
       "mark": [
        0,
        166
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/thai-nakorn-patana-co-ltd-672712-02272024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "S & J International Enterprises",
     "meta": [
      "26 January 2024",
      "21 CFR 211.22"
     ],
     "tags": [
      {
       "label": "Preparation not recorded"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Laboratory sample preparation is not documented, and weight print-outs are not retained.",
       "mark": [
        0,
        88
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/s-j-international-enterprises-public-company-limited-668482-01262024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Global Pharma Healthcare",
     "meta": [
      "20 October 2023",
      "21 CFR 211.22"
     ],
     "tags": [
      {
       "label": "Not recorded at the time"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "For example, your firm permitted the unacceptable practice of using pre-filled batch release documents.",
       "mark": [
        13,
        103
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/global-pharma-healthcare-private-limited-657325-10202023",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Similasan",
     "meta": [
      "11 September 2023",
      "21 CFR 211.194(a)"
     ],
     "tags": [
      {
       "label": "Not recorded at the time"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "For example, negative controls for sterility testing are not documented at the time of performance.",
       "mark": [
        0,
        99
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/similasan-ag-658878-09112023",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Safecor Health",
     "meta": [
      "5 September 2023",
      "21 CFR 211.22"
     ],
     "tags": [
      {
       "label": "Not recorded at the time"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "For example, our investigators observed partially completed and torn-up manufacturing records for a lot of children's acetaminophen and stacks of loose printed forms on a desk next to the repackaging area.",
       "mark": [
        136,
        204
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/safecor-health-llc-657886-09052023",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Cosmobeauti Laboratories & Manufacturing",
     "meta": [
      "11 August 2023",
      "21 CFR 211.22"
     ],
     "tags": [
      {
       "label": "Not recorded at the time"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "For example, your QU, which includes you and your regulatory consultant, failed to ensure that the review of batch production record steps was contemporaneously recorded.",
       "mark": [
        13,
        170
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/cosmobeauti-laboratories-manufacturing-inc-657682-08112023",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Sure-Biochem Laboratories",
     "meta": [
      "24 March 2023",
      "21 CFR 211.22(a)"
     ],
     "tags": [
      {
       "label": "Preparation not recorded"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "For example, your QU failed: To adequately retain documentation for the review, approval, or rejection, of laboratory testing materials such as buffers, reagents, and media.",
       "mark": [
        29,
        173
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/sure-biochem-laboratories-llc-646619-03242023",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Glenmark Pharmaceuticals",
     "meta": [
      "22 November 2022",
      "21 CFR 211.160(a)"
     ],
     "tags": [
      {
       "label": "Instrument not recorded"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "It is also not discussed in the investigation report if system suitability was met to ensure instrumentation readiness in the initial processing.",
       "mark": [
        0,
        145
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/glenmark-pharmaceuticals-limited-637314-11222022",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Advanced Cosmetic Research Laboratories",
     "meta": [
      "26 September 2022",
      "21 CFR 211.22(a) and (d)"
     ],
     "tags": [
      {
       "label": "Not recorded at the time"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "For example, regarding your batch record for (b)(4) Sunscreen SPF-30 lot (b)(4) : Finished drug \"Product Analysis Report\" used for batch release, was signed as reviewed and approved on March 23, 2022, even though the batch was still being filled on March 28, 2022.",
       "mark": [
        82,
        264
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/advanced-cosmetic-research-laboratories-inc-635176-09262022",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Green Wave Analytical",
     "meta": [
      "19 August 2022",
      "21 CFR 211.194(a)"
     ],
     "tags": [
      {
       "label": "Preparation not recorded"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "For example, laboratory records for the chemical and microbiological testing of drugs lacked the identification of the method used, documentation of a method's execution, identity of standards, reagents, and test kits used, identification of the sample's lot number for traceability, or equipment used (including, but not limited to, microbiological media, micro-pipette, and high performance liquid chromatography (HPLC) instrument).",
       "mark": [
        171,
        282
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/green-wave-analytical-llc-630965-08192022",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Verde Cosmetic Labs",
     "meta": [
      "30 March 2022",
      "21 CFR 211.67(b)"
     ],
     "tags": [
      {
       "label": "Instrument not recorded"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "However, there is no entry on your equipment maintenance log sheet that documents the use and cleaning of your filling line equipment for (b)(4) , Batch (b)(4) .",
       "mark": [
        0,
        161
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/verde-cosmetic-labs-llc-622534-03302022",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Dental Technologies",
     "meta": [
      "30 November 2021",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Instrument not recorded"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "However, your response lacks evidence of traceability confirming that the (b)(4) , identified as a potential cause of contamination, was adequately cleaned, and sanitized before use during manufacturing. • Your response acknowledges that the use of ancillary equipment is not documented in your batch records.",
       "mark": [
        206,
        309
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/dental-technologies-inc-612599-11302021",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Sanitor",
     "meta": [
      "29 November 2021",
      "21 CFR 211.22"
     ],
     "tags": [
      {
       "label": "Not recorded at the time"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Inadequate qua lity oversight over documentation During the review of a batch record for your (b)(4) hydroquinone (b)(4) drug product, batch (b)(4) , our investigators noted that production activities were not recorded contemporaneously.",
       "mark": [
        150,
        237
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/sanitor-corporation-616232-11292021",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Toyobo",
     "meta": [
      "19 August 2021",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Not recorded at the time"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Our inspection also cited additional weaknesses in the reliability of your documentation, including uncontrolled testing worksheets and deficient systems for reconciliation of laboratory documents.",
       "mark": [
        0,
        197
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/toyobo-co-ltd-614177-08192021",
     "urlLabel": "Read the letter"
    },
    {
     "title": "BBC Group",
     "meta": [
      "4 August 2021",
      "21 CFR 211.68(b)"
     ],
     "tags": [
      {
       "label": "Instrument not recorded"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "While your firm retained a static copy of laboratory records for review (i.e., paper record), they were inadequate as they did not preserve the dynamic record format of the full chromatographs to support test results and they did not include system suitability documentation that are part of the complete, original record.",
       "mark": [
        221,
        322
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/bbc-group-limited-614659-08042021",
     "urlLabel": "Read the letter"
    }
   ],
   "note": "57 of 540 letters, newest first after the ones the post quotes"
  },
  {
   "id": "left-out",
   "label": "Results produced, then left out or deleted",
   "count": 56,
   "records": [
    {
     "title": "Intas Pharmaceuticals",
     "meta": [
      "28 July 2023",
      "21 CFR 211.22"
     ],
     "tags": [
      {
       "label": "Results left out"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "The analyst stated to our investigator that he did not report all the test results, further stating that in some instances balance printouts were discarded in the trash.",
       "mark": [
        0,
        169
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/intas-pharmaceuticals-limited-652067-07282023",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Ava",
     "meta": [
      "14 April 2026",
      "21 CFR 211.194(a)"
     ],
     "tags": [
      {
       "label": "Results left out"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Both results were within your acceptable specification range. However, the more favorable result was reported.",
       "mark": [
        0,
        110
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/ava-inc-721180-04142026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Ultra Seal",
     "meta": [
      "14 March 2022",
      "21 CFR 211.68(b)"
     ],
     "tags": [
      {
       "label": "Results left out"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "During the inspection, our investigators observed that your analysts ran single injections on high performance liquid chromatography (HPLC) equipment without justification and saved the associated data in a folder entitled \"single runs,\" without a documented purpose.",
       "mark": [
        55,
        267
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/ultra-seal-corporation-624650-03142022",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Medgel",
     "meta": [
      "20 July 2023",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Data deleted or discarded"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Furthermore, our investigators could not review portions of humidity data between December 2022, and January 2023, because the raw data is not backed up and deleted every month.",
       "mark": [
        0,
        177
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/medgel-private-limited-654085-07202023",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Pritam International",
     "meta": [
      "27 October 2026",
      "21 CFR 211.194(a)"
     ],
     "tags": [
      {
       "label": "Results left out"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "However, on the next day, during plate reading and result recording, there was no visible microbiological growth on plates labeled as the same samples observed the day before.",
       "mark": [
        0,
        175
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/pritam-international-private-limited-738079-10272026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Eurofins SF Analytical Laboratories",
     "meta": [
      "6 October 2026",
      "21 CFR 211.194(a)"
     ],
     "tags": [
      {
       "label": "Data deleted or discarded"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Further, several samples with desiccated and cracked (b)(4) were recorded as 0 CFU and discarded without secondary analyst review.",
       "mark": [
        0,
        130
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/eurofins-sf-analytical-laboratories-inc-736056-10062026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Baxter International",
     "meta": [
      "29 September 2026",
      "21 CFR 211.42(c)"
     ],
     "tags": [
      {
       "label": "Data deleted or discarded"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "We also note that you mistakenly discarded multiple failing cephalosporin environmental samples before further analysis could be conducted.",
       "mark": [
        0,
        139
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/baxter-international-inc-733231-09292026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "SCA Pharmaceuticals",
     "meta": [
      "14 September 2026",
      "21 CFR 211.22(d)"
     ],
     "tags": [
      {
       "label": "Data deleted or discarded"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Specifically, our review of the data collected during the inspection revealed that your firm does not maintain the production video recordings which are used to determine root causes and corrective actions during investigations.",
       "mark": [
        83,
        228
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/sca-pharmaceuticals-llc-724202-09142026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Reliance Life Sciences",
     "meta": [
      "18 August 2026",
      "21 CFR 211.194(a)"
     ],
     "tags": [
      {
       "label": "Data deleted or discarded"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Specifically, reports were not saved with unique file names, resulting in data being overwritten after every (b)(4) tests.",
       "mark": [
        14,
        122
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/reliance-life-sciences-private-limited-730801-08182026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Dabur India",
     "meta": [
      "24 July 2026",
      "21 CFR 211.194(a)"
     ],
     "tags": [
      {
       "label": "Data deleted or discarded"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "For example, your analytical notebooks documented approximately (b)(4) microbiology plates for finished drug products and approximately (b)(4) media plates for testing (b)(4) samples as incubated, but the plates were physically absent from incubators with no documented explanation about their whereabouts or disposal.",
       "mark": [
        13,
        318
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/dabur-india-limited-728828-07242026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "BioMylz",
     "meta": [
      "13 July 2026",
      "21 CFR 211.22"
     ],
     "tags": [
      {
       "label": "Data deleted or discarded"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Our investigators discovered a garbage bag containing original data.",
       "mark": [
        0,
        68
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/biomylz-pvt-ltd-729483-07132026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Wizcure Pharmaa",
     "meta": [
      "24 June 2026",
      "21 CFR 211.194(a)"
     ],
     "tags": [
      {
       "label": "Data deleted or discarded"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Both management and a microbiologist confirmed that the original microbial plates were discarded and replaced with new plates.",
       "mark": [
        0,
        126
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/wizcure-pharmaa-private-limited-726378-06242026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Genzyme Ireland",
     "meta": [
      "22 June 2026",
      "21 CFR 211.194(a)"
     ],
     "tags": [
      {
       "label": "Data deleted or discarded"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your laboratory records were incomplete because quality control personnel used uncontrolled Review Checklists to unofficially document laboratory record reviews, which were subsequently discarded.",
       "mark": [
        48,
        196
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/genzyme-ireland-limited-728681-06222026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Huons",
     "meta": [
      "15 June 2026",
      "21 CFR 211.194(a)"
     ],
     "tags": [
      {
       "label": "Data deleted or discarded"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "However, your team leader had instructed staff to discard the bioburden plat es with significant growth and had manipulated camera timestamps to create backdated documentation.",
       "mark": [
        9,
        71
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/huons-co-ltd-724650-06152026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Zydus Lifesciences",
     "meta": [
      "2 June 2026",
      "21 CFR 211.22"
     ],
     "tags": [
      {
       "label": "Results left out"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your records submitted for talc identification testing by IR spectroscopy show that an out-of-specification (OOS) wavenumber result was removed from an infrared instrument report and multiple passing wavenumbers were added.",
       "mark": [
        84,
        223
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/zydus-lifesciences-limited-722576-06022026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Laboratorios Jaloma",
     "meta": [
      "22 May 2026",
      "21 CFR 211.68(b)"
     ],
     "tags": [
      {
       "label": "Data deleted or discarded"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "During the inspection, our investigators documented several chromatograph data files that could not be located in the storage folders on your GC computer.",
       "mark": [
        0,
        154
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/laboratorios-jaloma-sa-de-cv-725939-05222026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "GC America",
     "meta": [
      "14 May 2026",
      "21 CFR 211.68(b)"
     ],
     "tags": [
      {
       "label": "Data deleted or discarded"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "In addition, the data from the (b)(4) meter is automatically deleted when the laptop is shutdown, so no records were available to show that your QU reviewed this data.",
       "mark": [
        13,
        167
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/gc-america-inc-727602-05142026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Intas Pharmaceuticals",
     "meta": [
      "30 March 2026",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Results left out"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "You also discarded the initial OOS with insufficient supporting documentation and did not include it in your final reporting of the assay result.",
       "mark": [
        0,
        145
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/intas-pharmaceuticals-limited-721151-03302026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Patcos Cosmetics",
     "meta": [
      "12 March 2026",
      "21 CFR 211.194"
     ],
     "tags": [
      {
       "label": "Results left out"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Specifically, your QU failed to: Ensure adequate control over laboratory data including deliberate alteration of original data to conceal out-of-specification results (21 CFR 211.194).",
       "mark": [
        33,
        166
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/patcos-cosmetics-pvt-ltd-718220-03122026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Fareva Morton Grove",
     "meta": [
      "3 March 2026",
      "21 CFR 211.194(a)"
     ],
     "tags": [
      {
       "label": "Data deleted or discarded"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "However, your firm had discarded the plate without recording the microbial levels.",
       "mark": [
        0,
        82
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/fareva-morton-grove-719408-03032026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Tentamus India",
     "meta": [
      "3 March 2026",
      "21 CFR 211.22"
     ],
     "tags": [
      {
       "label": "Data deleted or discarded"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "For the method validation study, official records contained only handwritten values, while the original data was discarded in the garbage bags.",
       "mark": [
        0,
        143
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/tentamus-india-private-limited-720463-03032026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "A. Nelson",
     "meta": [
      "12 February 2026",
      "21 CFR 211.22(d)"
     ],
     "tags": [
      {
       "label": "Data deleted or discarded"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Furthermore, numerous analytical forms with unacceptable results were discarded that should have triggered investigations.",
       "mark": [
        0,
        122
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/nelson-co-ltd-720283-02122026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Unipack",
     "meta": [
      "19 December 2025",
      "21 CFR 211.194(a)"
     ],
     "tags": [
      {
       "label": "Results left out"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "For example, electronic records stored in a folder titled \" (b)(4) \" indicate that approximately (b)(4) sample injections were performed. However, results were generated only for approximately (b)(4) injections.",
       "mark": [
        0,
        211
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/unipack-llc-716621-12192025",
     "urlLabel": "Read the letter"
    },
    {
     "title": "DermaRite Industries",
     "meta": [
      "27 October 2025",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Results left out"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "It is noteworthy that the certificate of analysis did not reflect the actual results.",
       "mark": [
        0,
        85
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/dermarite-industries-llc-710997-10272025",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Taizhou Kangping Medical Science and Technology",
     "meta": [
      "9 October 2025",
      "21 CFR 211.160(b)"
     ],
     "tags": [
      {
       "label": "Data deleted or discarded"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "The inspection documented the deletion of several recent Excel spreadsheets that were used to perform suitability and assay cal culations.",
       "mark": [
        0,
        123
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/taizhou-kangping-medical-science-and-technology-co-ltd-711081-10092025",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Persōn & Covey",
     "meta": [
      "23 September 2025",
      "21 CFR 211.22"
     ],
     "tags": [
      {
       "label": "Results left out"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "You released the material after the (b)(4) sample obtained a passing result, which was the only test result attributed to bulk lot (b)(4) .",
       "mark": [
        0,
        137
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/person-covey-inc-711191-09232025",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Shiva Analyticals",
     "meta": [
      "23 July 2025",
      "21 CFR 211.22(d)"
     ],
     "tags": [
      {
       "label": "Data deleted or discarded"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "These discarded original documents included, but were not limited to, analytical balance weighing printouts, pH meter printouts, and analytical method verification records.",
       "mark": [
        0,
        172
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/shiva-analyticals-private-limited-707857-07232025",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Dynamic Blending Specialists",
     "meta": [
      "18 June 2025",
      "21 CFR 211.22"
     ],
     "tags": [
      {
       "label": "Data deleted or discarded"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Shred bins containing what appeared to be CGMP records were located in your manufacturing and warehouse areas.",
       "mark": [
        0,
        110
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/dynamic-blending-specialists-inc-701278-06182025",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Taizhou Jingshang Cosmetics Technology",
     "meta": [
      "2 April 2025",
      "21 CFR 211.194(a)"
     ],
     "tags": [
      {
       "label": "Data deleted or discarded"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "For example, the electronic data generated by the gas chromatography system was not appropriately backed up to a separate storage location and appeared to have been deleted from the system.",
       "mark": [
        13,
        189
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/taizhou-jingshang-cosmetics-technology-co-ltd-701945-04022025",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Yangzhou Sion Commodity",
     "meta": [
      "12 March 2025",
      "21 CFR 211.194(a)"
     ],
     "tags": [
      {
       "label": "Data deleted or discarded"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "The use of correction fluid (white-out) was also observed to make corrections on paper records documenting microbial analyses of finished products and raw materials.",
       "mark": [
        0,
        165
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/yangzhou-sion-commodity-co-ltd-699183-03122025",
     "urlLabel": "Read the letter"
    },
    {
     "title": "International Laboratories",
     "meta": [
      "10 March 2025",
      "21 CFR 211.68(b)"
     ],
     "tags": [
      {
       "label": "Data deleted or discarded"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "For example, our investigator documented numerous examples of deleted electronic raw data files.",
       "mark": [
        13,
        96
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/international-laboratories-corp-698522-03102025",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Granules India",
     "meta": [
      "26 February 2025"
     ],
     "tags": [
      {
       "label": "Data deleted or discarded"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Concerns with CGMP records A large amount of torn CGMP records were discovered in at least 15 plastic waste bags during the inspection, including analytical balance printouts and worksheets containing manufacturing and testing data.",
       "mark": [
        27,
        232
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/granules-india-limited-697115-02262025",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Aspen Pharmacare Holdings",
     "meta": [
      "24 February 2025",
      "21 CFR 211.68(b)"
     ],
     "tags": [
      {
       "label": "Results left out"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your operators obtained and printed a passing result after multiple production filter integrity tests failed. Your operators did not record or print the failing results.",
       "mark": [
        0,
        169
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/aspen-pharmacare-holdings-limited-701671-02242025",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Viatris",
     "meta": [
      "19 December 2024",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Results left out"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "The analyst, after consulting their supervisor, aborted the HPLC sample set sequence without providing adequate justification.",
       "mark": [
        0,
        126
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/viatris-inc-690897-12192024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "LCC",
     "meta": [
      "21 November 2024",
      "21 CFR 211.194(a)"
     ],
     "tags": [
      {
       "label": "Data deleted or discarded"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Additionally, raw data for melting point were also found in the trash and did not completely match the data recorded.",
       "mark": [
        0,
        117
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/lcc-ltd-688576-11212024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Unexo Lifesciences",
     "meta": [
      "6 November 2024"
     ],
     "tags": [
      {
       "label": "Data deleted or discarded"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Additionally the QC manager's computer was requested to review COAs and test procedures, however, when the laptop was provided all recent files and drives were apparently deleted before being presented to the investigators.",
       "mark": [
        98,
        223
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/unexo-lifesciences-private-limited-688163-11062024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Outin Futures",
     "meta": [
      "25 September 2024",
      "21 CFR 211.68(b)"
     ],
     "tags": [
      {
       "label": "Data deleted or discarded"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Specifically, electronic raw data used for release testing of batches (e.g., (b)(4) ) currently in the U.S. market was deleted and not accessible.",
       "mark": [
        0,
        146
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/outin-futures-corp-684688-09252024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Eugia Pharma Specialities",
     "meta": [
      "15 August 2024",
      "21 CFR 211.194(a)"
     ],
     "tags": [
      {
       "label": "Results left out"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your operators also did not appropriately document (b)(4) leaks and failures and performed inadequate (b)(4) monitoring.",
       "mark": [
        0,
        120
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/eugia-pharma-specialities-limited-681905-08152024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Jiangsu Hengrui Pharmaceuticals",
     "meta": [
      "11 July 2024",
      "21 CFR 211.22"
     ],
     "tags": [
      {
       "label": "Data deleted or discarded"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "For example, our inspection documented serious quality assurance (QA) deficiencies, such as discarded original CGMP records found stacked in a bag underneath a vehicle and in a nearby trash can, as well as your production manager's unrestricted access to blank production batch records and other CGMP documents without QA issuance.",
       "mark": [
        92,
        193
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/jiangsu-hengrui-pharmaceuticals-co-ltd-679790-07112024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Central Admixture Pharmacy Services",
     "meta": [
      "10 July 2024",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Results left out"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your response, regarding your firm's failure to report and investigate all out of specification finished product test results, states that \" (b)(4) personnel at the two remaining facilities will re-train on SOP-CAPS-4000317 'Investigation of Out of Specifications Results for CAPS Quality.'\" Documentation of employee training for this SOP was not provided.",
       "mark": [
        25,
        125
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/central-admixture-pharmacy-services-inc-687936-07102024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Landy International",
     "meta": [
      "12 June 2024",
      "21 CFR 211.68(b)"
     ],
     "tags": [
      {
       "label": "Data deleted or discarded"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "For example, investigators found numerous analysis reports, test methods, raw data calibration, and system directories in the GC computer's recycling bin.",
       "mark": [
        0,
        154
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/landy-international-679066-06122024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Fancystage Unipessoal",
     "meta": [
      "4 June 2024",
      "21 CFR 211.22"
     ],
     "tags": [
      {
       "label": "Data deleted or discarded"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "For example, employees were able to print out and discard documents (e.g., batch records) without adequate QU approval or reconciliation.",
       "mark": [
        13,
        137
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/fancystage-unipessoal-lda-678453-06042024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Grupo Quimico",
     "meta": [
      "30 April 2024",
      "21 CFR 211.194(a)"
     ],
     "tags": [
      {
       "label": "Results left out"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "During the inspection, our investigator found unprocessed and unreported high-performance liquid chromatography (HPLC) sample injections for several batches of (b)(4) drug product, which is marketed in the United States.",
       "mark": [
        0,
        220
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/grupo-quimico-srl-674010-04302024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Westwood Laboratories",
     "meta": [
      "17 April 2024",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Results left out"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Notably, your complaint report did not acknowledge the OOS and stated, \"The product does not feel like it is watery thin and would apply correctly as per the retains of the lot that were pulled and evaluated.\" Your response states you will revise the investigation and complaint procedures to include the pulling and testing of retain samples and retrain staff with the procedural improvements going forward.",
       "mark": [
        0,
        209
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/westwood-laboratories-llc-674728-04172024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "FirstCham",
     "meta": [
      "3 April 2024",
      "21 CFR 211.22"
     ],
     "tags": [
      {
       "label": "Data deleted or discarded"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "In addition, you approved an inadequate stability study and failed to ensure reliability of data relating to drug product quality (e.g., prefilled documents, deleted chromatographic data, inadequate investigations, etc.).",
       "mark": [
        131,
        219
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/firstcham-co-ltd-672903-04032024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Kilitch Healthcare India",
     "meta": [
      "28 March 2024",
      "21 CFR 211.194(a)"
     ],
     "tags": [
      {
       "label": "Results left out"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm stated that prior to the start of the inspection, where you admitted routine fabrication of environmental monitoring results, no single action limit excursion had been documented, however, FDA investigators observed the following during the inspection: 15 action level excursions for ISO 5 area environmental monitoring samples 13 action level excursions for personnel monitoring samples 5 action level excursions for ISO 7 area environmental…",
       "mark": [
        0,
        188
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/kilitch-healthcare-india-limited-672956-03282024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Amman Pharmaceutical Industries",
     "meta": [
      "14 February 2024",
      "21 CFR 211.194(a)"
     ],
     "tags": [
      {
       "label": "Data deleted or discarded"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "During our inspection, you confirmed that original data had been overwritten, and therefore could not be accessed.",
       "mark": [
        0,
        114
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/amman-pharmaceutical-industries-668867-02142024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Cipla",
     "meta": [
      "17 November 2023",
      "21 CFR 211.22(d)"
     ],
     "tags": [
      {
       "label": "Data deleted or discarded"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "The bags of scrap included, but were not limited to, numerous torn pieces of printer weigh slips pertaining to drug product packaging, and a microbiology laboratory sample label with Quality Assurance wet signatures.",
       "mark": [
        0,
        216
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/cipla-limited-660904-11172023",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Safecor Health",
     "meta": [
      "5 September 2023",
      "21 CFR 211.22"
     ],
     "tags": [
      {
       "label": "Data deleted or discarded"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "For example, our investigators observed partially completed and torn-up manufacturing records for a lot of children's acetaminophen and stacks of loose printed forms on a desk next to the repackaging area.",
       "mark": [
        13,
        131
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/safecor-health-llc-657886-09052023",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Dunagin Pharmaceuticals",
     "meta": [
      "22 February 2023",
      "21 CFR 211.22(a)"
     ],
     "tags": [
      {
       "label": "Data deleted or discarded"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "You stated the results would be discarded, and the tests would be reperformed by a different analyst.",
       "mark": [
        0,
        101
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/dunagin-pharmaceuticals-inc-dba-massco-dental-644335-02222023",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Kari Gran",
     "meta": [
      "30 November 2022",
      "21 CFR 211.188"
     ],
     "tags": [
      {
       "label": "Data deleted or discarded"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "During the inspection, our investigator identified that your batch production records contained the use of white-out correction liquid and crossed-out data entries, including entries for raw material lot number and supplier information.",
       "mark": [
        0,
        236
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/kari-gran-inc-640035-11302022",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Vi-Jon",
     "meta": [
      "31 March 2022",
      "21 CFR 211.68(b)"
     ],
     "tags": [
      {
       "label": "Data deleted or discarded"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "During the inspection, one of your employees opened the computer's recycle bin and noted that approximately (b)(4) files and folders were deleted.",
       "mark": [
        0,
        146
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/vi-jon-llc-622087-03312022",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Yusef Manufacturing Laboratories",
     "meta": [
      "8 February 2022",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Results left out"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "You reported the average of the passing results on your COA and released the product.",
       "mark": [
        0,
        85
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/yusef-manufacturing-laboratories-llc-621026-02082022",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Missouri Analytical Laboratories",
     "meta": [
      "30 September 2021",
      "21 CFR 211.68(b)"
     ],
     "tags": [
      {
       "label": "Data deleted or discarded"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Our investigators found approximately 36 deleted data files or folders in the recycle bin.",
       "mark": [
        0,
        90
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/missouri-analytical-laboratories-inc-615319-09302021",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Toyobo",
     "meta": [
      "19 August 2021",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Results left out"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "…data for ISO 5 (Grade A) was reported as ISO 7 (Grade B) when particles results were higher than alert levels. • Operators failed to report ISO 5 (Grade A) airborne particulates values using a portable particulate counter, instead they repeated the monitoring of airborne particulates",
       "mark": [
        114,
        285
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/toyobo-co-ltd-614177-08192021",
     "urlLabel": "Read the letter"
    },
    {
     "title": "BBC Group",
     "meta": [
      "4 August 2021",
      "21 CFR 211.68(b)"
     ],
     "tags": [
      {
       "label": "Data deleted or discarded"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "However, your firm stated that all testing data from 2018 to 2020 was lost approximately one month prior to the initiation of our inspection.",
       "mark": [
        0,
        141
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/bbc-group-limited-614659-08042021",
     "urlLabel": "Read the letter"
    }
   ],
   "note": "56 of 540 letters, newest first after the ones the post quotes"
  },
  {
   "id": "no-review",
   "label": "No real review of the lab data",
   "count": 50,
   "records": [
    {
     "title": "Intas Pharmaceuticals",
     "meta": [
      "28 July 2023",
      "21 CFR 211.160(a)"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your procedure lacked a requirement for supervisory approval and other controls such as data review and justification to consistently document when and why an analyst manually performs integration events.",
       "mark": [
        0,
        204
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/intas-pharmaceuticals-limited-652067-07282023",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Ultra Seal",
     "meta": [
      "14 March 2022",
      "21 CFR 211.22(a)"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "Yet, since at least early 2021, your QU continued to release numerous drug product batches based on test results obtained from these unvalidated test methods.",
       "mark": [
        0,
        158
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/ultra-seal-corporation-624650-03142022",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Pritam International",
     "meta": [
      "27 October 2026",
      "21 CFR 211.22"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your QU failed to exercise its authority and responsibilities over your drug manufacturing operations, including ensuring the data integrity of your records.",
       "mark": [
        0,
        157
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/pritam-international-private-limited-738079-10272026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Rohto Pharmaceutical",
     "meta": [
      "14 October 2026",
      "21 CFR 211.194(a)"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "Widespread falsification across many staff members, multiple record types, and over an extended period of time went unchecked, reflecting a systemic quality failure and demonstrating a general failure of senior managers in your company to exercise their responsibility to ensure integrity of manufacturing and laboratory records.",
       "mark": [
        0,
        164
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/rohto-pharmaceutical-co-ltd-733215-10142026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Eurofins SF Analytical Laboratories",
     "meta": [
      "6 October 2026",
      "21 CFR 211.194(a)"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "Additionally, your data review procedure is deficient in that it does not require secondary verification when an initial plate count is recorded as 0 colony forming units (CFU), creating a systemic gap where microbial growth can go undetected.",
       "mark": [
        14,
        171
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/eurofins-sf-analytical-laboratories-inc-736056-10062026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "SnugZ USA",
     "meta": [
      "28 September 2026",
      "21 CFR 211.192"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "Adequate review of all production and test records, including deviations, OOS results, and audit trails, prior to releasing drug product to the market (21 CFR 211.192).",
       "mark": [
        0,
        168
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/snugz-usa-inc-735284-09282026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Auriga Research",
     "meta": [
      "12 August 2026",
      "21 CFR 211.22(d)"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your QU reviewed and approved investigations that did not thoroughly investigate unexplained discrepancies or failures of a drug product to meet any of its specifications.",
       "mark": [
        0,
        171
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/auriga-research-pvt-ltd-730694-08122026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Dabur India",
     "meta": [
      "24 July 2026",
      "21 CFR 211.22(a)"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "While these inaccuracies did not involve out-of-specification results, your QU signed off on these records without ensuring the consistency and accuracy of the data.",
       "mark": [
        0,
        165
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/dabur-india-limited-728828-07242026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Umendra Life Sciences",
     "meta": [
      "2 June 2026",
      "21 CFR 211.22"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "In particular, your QU did not adequately review or approve methods used by your contract laboratory, and review and approve data to ensure results are supported by accurate data.",
       "mark": [
        0,
        179
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/umendra-life-sciences-private-limited-721752-06022026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Gopaldas Visram",
     "meta": [
      "2 June 2026",
      "21 CFR 211.22"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "For example, your QU failed to assure that contract facilities are testing according to your procedures which require you to follow current United States Pharmacopeia (USP) specifications and that results are supported by sufficient information to provide an accurate determination of compliance for identification of talc and absence of asbestos.",
       "mark": [
        13,
        244
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/gopaldas-visram-co-ltd-721755-06022026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Zydus Lifesciences",
     "meta": [
      "2 June 2026",
      "21 CFR 211.22"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your QU failed in its responsibility to maintain data integrity and provide adequate oversight of testing procedures, demonstrating a lack of authority and control over critical quality decisions.",
       "mark": [
        0,
        196
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/zydus-lifesciences-limited-722576-06022026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Laboratorios Dr. Collado",
     "meta": [
      "2 June 2026",
      "21 CFR 211.22"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "For example, your firm did not review or approve test methods and specifications for testing asbestos in talc and failed to oversee your contract laboratory ensuring that the facility used a scientifically sound and fit for purpose method.",
       "mark": [
        0,
        156
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/laboratorios-dr-collado-sa-723285-06022026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Microbiological Testing & Consulting",
     "meta": [
      "16 March 2026",
      "21 CFR 211.22"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "As noted in the prior charge, your quality unit did not have adequate oversight of documentation, media qualification, and other critical microbiology laboratory programs.",
       "mark": [
        30,
        171
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/microbiological-testing-consulting-llc-720374-03162026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Unipack",
     "meta": [
      "19 December 2025",
      "21 CFR 211.194(a)"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm lacked evidence to demonstrate your laboratory manager and quality unit (QU) reviewed the raw data for these injections.",
       "mark": [
        0,
        130
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/unipack-llc-716621-12192025",
     "urlLabel": "Read the letter"
    },
    {
     "title": "LiquidCapsule Manufacturing",
     "meta": [
      "19 December 2025",
      "21 CFR 211.188"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "Information provided by your firm for batch (b)(4) indicates that this batch was distributed on (b)(4) , although the \"QA Checklist\" for batch record review and release was not completed.",
       "mark": [
        0,
        187
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/liquidcapsule-manufacturing-llc-717069-12192025",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Seaway Pharma",
     "meta": [
      "1 December 2025",
      "21 CFR 211.22(d)"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "QA-009, Revision 01, and between April 2024 and May 2025, released numerous batches of drug products for distribution prior to reviewing all test results to ensure they met specifications.",
       "mark": [
        58,
        187
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/seaway-pharma-inc-717355-12012025",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Siddha Flower Essences",
     "meta": [
      "4 November 2025",
      "21 CFR 211.22(a)"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "For example, your QU failed to ensure: Established procedures were followed (21 CFR 211.22(d)) Batch records were reviewed before drug product release (21 CFR 211.22(a)) Use of qualified contract testing laboratories (21 CFR 211.22(a)) Adequate effectiveness testing of the preservative system (21 CFR 211.160(b)) Adequate production and process controls were established (21 CFR 211.100(a)) Your firm's quality systems are inadequate.",
       "mark": [
        95,
        169
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/siddha-flower-essences-llc-dba-siddha-remedies-713217-11042025",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Owen Biosciences",
     "meta": [
      "30 October 2025",
      "21 CFR 211.192"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "For example, your QU failed to ensure: Review of production and control records to ensure completeness and accuracy (21 CFR 211.192).",
       "mark": [
        39,
        133
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/owen-biosciences-inc-710275-10302025",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Uriel Pharmacy",
     "meta": [
      "21 October 2025",
      "21 CFR 211.160(b)"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "For example, the (b)(4) Microbiology System validation report is incomplete and was not reviewed and approved by your firm.",
       "mark": [
        0,
        123
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/uriel-pharmacy-inc-709977-10212025",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Taizhou Kangping Medical Science and Technology",
     "meta": [
      "9 October 2025",
      "21 CFR 211.160(b)"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your QC Supervisor/Manager confirmed that the Excel spreadsheets that were relied upon to generate the finished product quality standards, had not been validated, controlled, retained, or quality verified for data integrity before they were used for product release.",
       "mark": [
        0,
        266
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/taizhou-kangping-medical-science-and-technology-co-ltd-711081-10092025",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Amneal Pharmaceuticals",
     "meta": [
      "27 August 2025",
      "21 CFR 211.160(b)"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "The analyst responsible for the (b)(4) verification of the gel-clot assessment was unable to adequately observe or verify the process due to the primary microbiologist's rapid assessment. Despite this basic deficiency, the secondary analyst signed off on the verification.",
       "mark": [
        0,
        272
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/amneal-pharmaceuticals-llc-709894-08272025",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Shiva Analyticals",
     "meta": [
      "23 July 2025",
      "21 CFR 211.22(d)"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your QU failed to ensure the reliability and integrity of analytical testing data.",
       "mark": [
        0,
        82
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/shiva-analyticals-private-limited-707857-07232025",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Medical Chemical",
     "meta": [
      "9 July 2025",
      "21 CFR 211.194(a)"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "Establishment and review of adequate laboratory records which include all data obtained during testing (21 CFR 211.194(a)).",
       "mark": [
        0,
        123
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/medical-chemical-corporation-706007-07092025",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Exela Pharma Sciences",
     "meta": [
      "2 July 2025",
      "21 CFR 211.194(a)"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "An independent review of the plate count by a second analyst to assure accuracy of the data was not conducted.",
       "mark": [
        0,
        110
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/exela-pharma-sciences-llc-709859-07022025",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Evi Labs",
     "meta": [
      "14 May 2025",
      "21 CFR 211.22(a)"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "Furthermore, your quality unit failed to reject topical drug products for distribution which either failed microbial limits testing or had not been subjected to finished product testing for potency.",
       "mark": [
        13,
        198
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/evi-labs-llc-705846-05142025",
     "urlLabel": "Read the letter"
    },
    {
     "title": "BEO Pharma",
     "meta": [
      "9 April 2025",
      "21 CFR 211.22(a)"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your QU approved the release of this batch, which stipulated all required test results for this batch were complete on December 24, 2023.",
       "mark": [
        0,
        137
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/beo-pharma-inc-dba-beo-pharmaceuticals-inc-701364-04092025",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Chara Biologics",
     "meta": [
      "17 January 2025",
      "21 CFR 211.22(a)"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "However, your firm does not receive documentation, such as production records or test results, for each lot received for approval or rejection by your firm before distribution.",
       "mark": [
        9,
        175
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/chara-biologics-inc-698004-01172025",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Viatris",
     "meta": [
      "19 December 2024",
      "21 CFR 211.192"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "You repeatedly accepted these conclusions, despite insufficient justification.",
       "mark": [
        0,
        78
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/viatris-inc-690897-12192024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Indoco Remedies",
     "meta": [
      "16 December 2024",
      "21 CFR 211.22(a) and 211.22(d)"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "Warning and error messages in the Empower Message Center included in your chromatography data software are not reviewed.",
       "mark": [
        0,
        120
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/indoco-remedies-limited-691594-12162024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Unexo Lifesciences",
     "meta": [
      "6 November 2024",
      "21 CFR 211.194(a)"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your quality management acknowledged you did not have the data for the peel strength and rolling ball analyses for batch (b)(4) , and provided no explanation when asked how you released the batch without the data.",
       "mark": [
        0,
        213
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/unexo-lifesciences-private-limited-688163-11062024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Analytical Food Laboratories",
     "meta": [
      "10 October 2024",
      "21 CFR 211.22"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your quality unit (QU) lacked adequate oversight of your contract testing operations.",
       "mark": [
        0,
        85
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/analytical-food-laboratories-inc-687513-10102024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Intercos Europe",
     "meta": [
      "15 August 2024",
      "21 CFR 211.194(a)"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "In addition, your procedure requires laboratory equipment to be operated at predetermined conditions, but it does not require peer review to verify these conditions and the data generated from your testing process.",
       "mark": [
        13,
        214
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/intercos-europe-spa-682273-08152024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Greco Gas",
     "meta": [
      "12 August 2024",
      "21 CFR 211.22(a)"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "For example, your QU released medical gases without adequately reviewing the finished batch records or determining that each batch met all quality attributes, including identity, assay, impurities, and labeling.",
       "mark": [
        13,
        211
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/greco-gas-inc-683090-08122024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Aerosol and Liquid Packaging",
     "meta": [
      "24 July 2024",
      "21 CFR 211.194(a)"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "For example, you failed to ensure: Laboratory records include complete data derived from all tests to assure compliance (21 CFR 211.194(a)).",
       "mark": [
        35,
        140
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/aerosol-and-liquid-packaging-inc-676746-07242024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Central Admixture Pharmacy Services",
     "meta": [
      "10 July 2024",
      "21 CFR 211.188"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "In addition, no response was provided regarding the (b)(4) test results, found in your record storage room, that were not reviewed and saved into the official batch records.",
       "mark": [
        13,
        173
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/central-admixture-pharmacy-services-inc-687936-07102024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Optikem International",
     "meta": [
      "20 June 2024",
      "21 CFR 211.22(a)"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "Ensure that production and laboratory records were adequately reviewed for errors (21 CFR 211.22(a)).",
       "mark": [
        0,
        101
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/optikem-international-inc-680264-06202024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "GFA Production Xiamen",
     "meta": [
      "13 June 2024",
      "21 CFR 211.194(a)"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "Additionally, although you provided a summary of test results from your contract testing laboratory showing all batches met specification, you did not provide nor indicate you have assessed your in-house HPLC test results for any OOS results or inconsistencies with the reported release testing results.",
       "mark": [
        139,
        303
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/gfa-production-xiamen-co-ltd-678364-06132024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Fancystage Unipessoal",
     "meta": [
      "4 June 2024",
      "21 CFR 211.22"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "Additionally, your QU did not adequately review the accuracy and integrity of data to assure the quality of the drugs you manufactured and released.",
       "mark": [
        14,
        148
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/fancystage-unipessoal-lda-678453-06042024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Grupo Quimico",
     "meta": [
      "30 April 2024",
      "21 CFR 211.194(a)"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "The printed data for these batches, reviewed by your QU, failed to include these OOS results or indicate that additional sample analysis had been conducted.",
       "mark": [
        0,
        156
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/grupo-quimico-srl-674010-04302024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Amman Pharmaceutical Industries",
     "meta": [
      "14 February 2024",
      "21 CFR 211.22(a)"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "For example, your QU failed to: Ensure that production and laboratory records were adequately reviewed for errors, adequate laboratory facilities were used by your firm, and that personnel performed aseptic operations appropriately.",
       "mark": [
        32,
        232
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/amman-pharmaceutical-industries-668867-02142024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "S & J International Enterprises",
     "meta": [
      "26 January 2024",
      "21 CFR 211.22"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "Lastly, your QU only reviews analytical results entered into your enterprise system and does not review raw analytical data before releasing quarantined materials or finished drug products.",
       "mark": [
        8,
        189
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/s-j-international-enterprises-public-company-limited-668482-01262024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "MiMedx Group",
     "meta": [
      "20 December 2023",
      "21 CFR 211.84(a)"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "According to your PCM (b)(4) specification, SPC300.034 (effective8/24/22), results of \"composition\" testing (also referred to as \"concentration analysis\") are not required for release.",
       "mark": [
        75,
        184
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/mimedx-group-inc-662942-12202023",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Intas Pharmaceuticals",
     "meta": [
      "21 November 2023",
      "21 CFR 211.22"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "In addition, there was a lack of QA department review and oversight of visual inspection records, and your firm continued this egregious pattern of recording and altering defect counts.",
       "mark": [
        0,
        185
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/intas-pharmaceuticals-limited-662868-11212023",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Similasan",
     "meta": [
      "11 September 2023",
      "21 CFR 211.22(a)"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "…that drug products conform to appropriate standards of identity, strength, quality, and purity (21 CFR 211.160(b)). • Adequate procedures to ensure that laboratory records included complete data (21 CFR 211.194(a))",
       "mark": [
        119,
        215
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/similasan-ag-658878-09112023",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Zermat International",
     "meta": [
      "6 April 2023",
      "21 CFR 211.22"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "In addition, discrepancies related to OOS values were noted during the inspection but not identified by your quality unit at the time of release.",
       "mark": [
        13,
        145
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/zermat-international-sa-de-cv-647232-04062023",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Glenmark Pharmaceuticals",
     "meta": [
      "22 November 2022",
      "21 CFR 211.160(a)"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "The procedure does not require supervisory approval for manually entering timed integration events, a review of the original system integrated chromatogram and justification for manually entering the timed events.",
       "mark": [
        0,
        213
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/glenmark-pharmaceuticals-limited-637314-11222022",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Nephron Pharmaceuticals",
     "meta": [
      "21 October 2022",
      "21 CFR 211.194(a)(8)"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "Laboratory records are deficient in that they do not include the initials and signatu re of the second person reviewing the record for accuracy (21 CFR 211.194 (a)(8)).",
       "mark": [
        0,
        77
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/nephron-pharmaceuticals-corporation-dba-nephron-sterile-compounding-center-llc-644180-10212022",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Beijing Xinggu Lvsan Technology",
     "meta": [
      "5 October 2022",
      "21 CFR 211.22"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "For example: Your batch records lacked information on the drug product release date and were not signed by your QU.",
       "mark": [
        13,
        115
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/beijing-xinggu-lvsan-technology-co-ltd-formerly-known-beijing-lvsan-technology-co-ltd-633904",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Green Wave Analytical",
     "meta": [
      "19 August 2022",
      "21 CFR 211.22(a)"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "For example, your written procedures did not address QU oversight and responsibilities including the authority to review laboratory records for errors and to ensure your firm maintains adequate laboratory facilities.",
       "mark": [
        13,
        150
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/green-wave-analytical-llc-630965-08192022",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Verde Cosmetic Labs",
     "meta": [
      "30 March 2022",
      "21 CFR 211.165(b)"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "For example, your QU failed to ensure the following: Microbiological testing was performed and reviewed prior to release for each batch of drug product (21 CFR 211.165(b)).",
       "mark": [
        53,
        172
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/verde-cosmetic-labs-llc-622534-03302022",
     "urlLabel": "Read the letter"
    }
   ],
   "note": "50 of 540 letters, newest first after the ones the post quotes"
  },
  {
   "id": "raw-data",
   "label": "Raw or electronic data not kept or not reviewed",
   "count": 47,
   "records": [
    {
     "title": "Intas Pharmaceuticals",
     "meta": [
      "28 July 2023",
      "21 CFR 211.194(a)"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "Paper printouts for the (b)(4) determinations and pH printouts could not be reconciled for (b)(4) injection, (b)(4) mg, process validation batch (b)(4) .",
       "mark": [
        0,
        153
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/intas-pharmaceuticals-limited-652067-07282023",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Ava",
     "meta": [
      "14 April 2026"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "In addition, chromatograms from trial injections were not saved in the analytical testing system or as part of your official batch record, creating opportunities to compromise the integrity of analytical data used for making batch release decisions.",
       "mark": [
        0,
        138
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/ava-inc-721180-04142026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Natural Essentials",
     "meta": [
      "10 November 2026",
      "21 CFR 211.194(a)"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "During the inspection, you admitted to preserving raw chromatographic data but failing to retain the processed chromatograms.",
       "mark": [
        0,
        125
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/natural-essentials-inc-738543-11102026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Pritam International",
     "meta": [
      "27 October 2026",
      "21 CFR 211.194(a)"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "You lacked complete and original laboratory data demonstrating that the required testing was performed.",
       "mark": [
        0,
        103
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/pritam-international-private-limited-738079-10272026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Eurofins SF Analytical Laboratories",
     "meta": [
      "6 October 2026",
      "21 CFR 211.192"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "Without photographic evidence of plate conditions at the time of reading, there is no basis to retroactively confirm any result.",
       "mark": [
        0,
        128
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/eurofins-sf-analytical-laboratories-inc-736056-10062026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Empower Clinic Services",
     "meta": [
      "18 September 2026"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "The documents provided show no records for (b)(4) .",
       "mark": [
        0,
        51
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/empower-clinic-services-llc-dba-empower-pharmacy-738238-09182026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Happy Farm Botanicals",
     "meta": [
      "1 September 2026",
      "21 CFR 211.166(a)"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "Multiple timepoints within your a ccelerated stability study were reported as \"Not Available\" and you identified failing results at (b)(4) for viscosity, which you did not investigate.",
       "mark": [
        45,
        93
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/happy-farm-botanicals-inc-731926-09012026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "K.C. Pharmaceuticals",
     "meta": [
      "12 August 2026",
      "21 CFR 211.166(a)"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "In your response, you acknowledge that initial forced degradation studies for the current OTC (b)(4) formulations could not be located, and you commit to repeating these studies and creating an action plan based on the results.",
       "mark": [
        0,
        134
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/kc-pharmaceuticals-inc-729870-08122026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Auriga Research",
     "meta": [
      "12 August 2026",
      "21 CFR 211.194(a)"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "While your summary reports included final plate counts, your raw data test sheets for some of the samples covered in these reports lacked complete documentation of plate counts.",
       "mark": [
        0,
        177
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/auriga-research-pvt-ltd-730694-08122026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Dabur India",
     "meta": [
      "24 July 2026",
      "21 CFR 211.194(a)"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "In addition, during the inspection you could not produce the test procedures, analytical workbooks, or test data sheets to support the reported certificate of analysis results for approximately (b)(4) batches of U.S. marketed drug products.",
       "mark": [
        13,
        240
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/dabur-india-limited-728828-07242026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "BioMylz",
     "meta": [
      "13 July 2026",
      "21 CFR 211.22"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "Specifically, you did not retain original data supporting laboratory test results used to release commercial batches, and you were not able to make this data available for FDA review.",
       "mark": [
        0,
        183
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/biomylz-pvt-ltd-729483-07132026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Umendra Life Sciences",
     "meta": [
      "2 June 2026",
      "21 CFR 211.22"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "For tests conducted for asbestos, data does not include expansion of spectra at the required wavenumber of (b)(4) cm-1 and the range of (b)(4) cm-1 to (b)(4) cm-1 was covered in by the spectral analysis.",
       "mark": [
        0,
        203
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/umendra-life-sciences-private-limited-721752-06022026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Pharmathen International",
     "meta": [
      "27 May 2026",
      "21 CFR 211.160(a)"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "For example, you did not have raw data and information related to sample preparation and the batch/sample identification number available for review.",
       "mark": [
        0,
        149
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/pharmathen-international-sa-723680-05272026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Laboratorios Jaloma",
     "meta": [
      "22 May 2026",
      "21 CFR 211.68(b)"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm confirmed that you did not back up the electronic data located on the GC computer.",
       "mark": [
        0,
        92
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/laboratorios-jaloma-sa-de-cv-725939-05222026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Sato Pharmaceutical",
     "meta": [
      "18 May 2026",
      "21 CFR 211.166(a)"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "These impurity peaks were visible in the chromatograms but were not identified or adequately evaluated against established acceptance criteria.",
       "mark": [
        0,
        143
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/sato-pharmaceutical-co-ltd-723059-05182026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Microbiological Testing & Consulting",
     "meta": [
      "16 March 2026",
      "21 CFR 211.22"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "It appears that your firm did not make all requested OOS/OOL test data available during the inspection.",
       "mark": [
        0,
        103
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/microbiological-testing-consulting-llc-720374-03162026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Fareva Morton Grove",
     "meta": [
      "3 March 2026",
      "21 CFR 211.194(a)"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "You were also unable to provide complete (b)(4) microbial sampling results from the (b)(4) .",
       "mark": [
        0,
        92
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/fareva-morton-grove-719408-03032026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "AQ USA",
     "meta": [
      "12 February 2026",
      "21 CFR 211.166(a)"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "During the inspection you were unable to provide raw data for any microbiological testing conducted.",
       "mark": [
        0,
        100
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/aq-usa-inc-dba-ross-healthcare-inc-719517-02122026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Fulijaya Manufacturing",
     "meta": [
      "14 January 2026",
      "21 CFR 211.194(a)"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "For example, our investigator asked for raw data for microbiological release and stability testing of your over-the-counter (OTC) drug products prior to May 2025 and your firm's representative stated that the logbooks were not available.",
       "mark": [
        13,
        124
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/fulijaya-manufacturing-sdn-bhd-719172-01142026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "CDL Services",
     "meta": [
      "24 November 2025"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "…attributes to be tested at each station (timepoint) Access to Information During Inspection During the inspection, the gas chromatograph and the associated CGMP computer system were not available to the inspection team",
       "mark": [
        116,
        219
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/cdl-services-inc-dba-technichem-713877-11242025",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Taizhou Kangping Medical Science and Technology",
     "meta": [
      "9 October 2025",
      "21 CFR 211.160(b)"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "Specifically, Excel worksheets used to perform chromatogram calculations were not retained, and access accounts to the GC and HPLC workstations were shared by job title and were not attributable to the individual analyst.",
       "mark": [
        14,
        90
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/taizhou-kangping-medical-science-and-technology-co-ltd-711081-10092025",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Persōn & Covey",
     "meta": [
      "23 September 2025",
      "21 CFR 211.22"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "Also, audit trails are not independently reviewed after analysis or at an established frequency; and there is no review of the electronic raw data or printed hard copy data.",
       "mark": [
        101,
        172
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/person-covey-inc-711191-09232025",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Wisconsin Pharmacal Company",
     "meta": [
      "22 August 2025",
      "21 CFR 211.68(b)"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "You do not have written procedures to review electronic data or integration to ensure data reliability for batch release.",
       "mark": [
        0,
        121
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/wisconsin-pharmacal-company-llc-710329-08222025",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Exela Pharma Sciences",
     "meta": [
      "2 July 2025"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "A single analyst reads environmental plate counts, takes pictures only of the positive counts, and then enters results in the (b)(4) software system.",
       "mark": [
        0,
        149
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/exela-pharma-sciences-llc-709859-07022025",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Dynamic Blending Specialists",
     "meta": [
      "18 June 2025",
      "21 CFR 211.22"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "Water monitoring records stored on an employee's personal computer could not be provided.",
       "mark": [
        0,
        89
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/dynamic-blending-specialists-inc-701278-06182025",
     "urlLabel": "Read the letter"
    },
    {
     "title": "NWL Netherlands Services",
     "meta": [
      "1 April 2025",
      "21 CFR 211.68(b)"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "Furthermore, your firm did not adequately maintain backups of data generated by your laboratory equipment.",
       "mark": [
        13,
        105
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/nwl-netherlands-services-bv-701206-04012025",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Yangzhou Sion Commodity",
     "meta": [
      "12 March 2025",
      "21 CFR 211.194(a)"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm did not retain original data to support testing of components used to manufacture OTC drug products for the U.S. market.",
       "mark": [
        0,
        130
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/yangzhou-sion-commodity-co-ltd-699183-03122025",
     "urlLabel": "Read the letter"
    },
    {
     "title": "International Laboratories",
     "meta": [
      "10 March 2025",
      "21 CFR 211.194(a)"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your laboratory records lacked complete and reliable original data to support the chromatographic analyses performed on over-the-counter (OTC) drug products and components.",
       "mark": [
        0,
        172
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/international-laboratories-corp-698522-03102025",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Annovex Pharma",
     "meta": [
      "5 March 2025"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "Regarding your firm's failure to provide our investigators with your 2023 media fill records due to technical issues, you provided a new procedure, SOP-0261 Retention of Records, which details document retention requirements; however, this procedure does not specify how and where documents will be retained or how these retained documents will be controlled.",
       "mark": [
        0,
        116
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/annovex-pharma-inc-698115-03052025",
     "urlLabel": "Read the letter"
    },
    {
     "title": "LCC",
     "meta": [
      "21 November 2024",
      "21 CFR 211.194(a)"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "Upon request to review the electronic raw data for your assay test results generated for drug products distri buted to the U.S. market, your plant manager indicated the data was lost.",
       "mark": [
        136,
        183
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/lcc-ltd-688576-11212024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Unexo Lifesciences",
     "meta": [
      "6 November 2024"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "Access to Information During Inspection During the inspection, the only computer alleged to have all the electronic CGMP data, which was not backed up, was not available because the QC analyst took the computer home and could not be reached after multiple attempts.",
       "mark": [
        63,
        265
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/unexo-lifesciences-private-limited-688163-11062024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Outin Futures",
     "meta": [
      "25 September 2024",
      "21 CFR 211.68(b)"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm did not adequately maintain backups of data generated by your laboratory equipment.",
       "mark": [
        0,
        93
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/outin-futures-corp-684688-09252024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Brassica Pharma",
     "meta": [
      "11 July 2024",
      "21 CFR 211.42(c)(10)"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "For example, non-viable particulate monitoring is not performed during filling operations, only before and after. These data, while collected, are not recorded.",
       "mark": [
        0,
        160
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/brassica-pharma-pvt-ltd-679005-07112024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Optikem International",
     "meta": [
      "20 June 2024",
      "21 CFR 211.194"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "For example, our inspection found missing original data in your laboratory and production operations (21 CFR 211.194 & 211.100).",
       "mark": [
        0,
        128
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/optikem-international-inc-680264-06202024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Laboratorio Magnachem International",
     "meta": [
      "18 June 2024",
      "21 CFR 211.68(b)"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "Furthermore, your firm did not adequately maintain backups of data generated by your laboratory equipment.",
       "mark": [
        0,
        106
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/laboratorio-magnachem-international-673796-06182024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "GFA Production Xiamen",
     "meta": [
      "13 June 2024",
      "21 CFR 211.194(a)"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm performed chemical testing of drug products using high performance liquid chromatography (HPLC) but did not include complete data to support the analysis performed.",
       "mark": [
        0,
        174
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/gfa-production-xiamen-co-ltd-678364-06132024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Grupo Quimico",
     "meta": [
      "30 April 2024",
      "21 CFR 211.160(b)"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "For example, your procedures did not require evaluation of electronic data which included reprocessed sample integration, aborted runs, single injection data, and electronic audit trails (when available).",
       "mark": [
        0,
        204
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/grupo-quimico-srl-674010-04302024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Amman Pharmaceutical Industries",
     "meta": [
      "14 February 2024",
      "21 CFR 211.194(a)"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm did not retain original source data (metadata) from the HPLC equipment to ensure audit trails could be properly reviewed.",
       "mark": [
        0,
        131
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/amman-pharmaceutical-industries-668867-02142024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "S & J International Enterprises",
     "meta": [
      "26 January 2024",
      "21 CFR 211.188"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "However, you could not provide the permanent version of these records and stated that only production staff and production supervisors, and not the QU, have access to the scanned sheets and logs.",
       "mark": [
        9,
        195
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/s-j-international-enterprises-public-company-limited-668482-01262024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Lex",
     "meta": [
      "17 August 2023",
      "21 CFR 211.68(b)"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "Furthermore, your firm did not adequately maintain backups of data generated by your laboratory equipment.",
       "mark": [
        0,
        106
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/lex-inc-656056-08172023",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Sure-Biochem Laboratories",
     "meta": [
      "24 March 2023",
      "21 CFR 211.194(a)"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "Furthermore, you were unable to provide raw data to support the suitability of your alternative methods for each drug tested.",
       "mark": [
        0,
        125
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/sure-biochem-laboratories-llc-646619-03242023",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Glenmark Pharmaceuticals",
     "meta": [
      "22 November 2022",
      "21 CFR 211.160(a)"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "The investigation report did not include the full-scale chromatographic run, information of the integration parameters or the chromatograms for the sample standard and blanks.",
       "mark": [
        0,
        175
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/glenmark-pharmaceuticals-limited-637314-11222022",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Invitrx Therapeutics",
     "meta": [
      "9 November 2022",
      "21 CFR 610.12"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm did not document performance or results of sterility testing of your products that was conducted in-house from January 2021 to March 2022.",
       "mark": [
        0,
        148
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/invitrx-therapeutics-inc-630712-11092022",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Beijing Xinggu Lvsan Technology",
     "meta": [
      "5 October 2022",
      "21 CFR 211.22"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your QU could not locate the laboratory test results in your electronic system (the New Century System) and there was inadequate backup of the electronic data.",
       "mark": [
        0,
        159
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/beijing-xinggu-lvsan-technology-co-ltd-formerly-known-beijing-lvsan-technology-co-ltd-633904",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Gordon Laboratories",
     "meta": [
      "17 August 2022",
      "21 CFR 211.192"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "Furthermore, during the inspection, data to support the quality of the water system before July 2021, was not available nor provided.",
       "mark": [
        0,
        133
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/gordon-laboratories-inc-631432-08172022",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Monarch PCM",
     "meta": [
      "10 June 2022",
      "21 CFR 211.22"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "CGMP records, such as microbiological notebooks, logbooks, and BCC-related microbiological laboratory investigation reports (MLIRs) were missing, and no investigation was initiated.",
       "mark": [
        0,
        181
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/monarch-pcm-llc-620779-06102022",
     "urlLabel": "Read the letter"
    },
    {
     "title": "BBC Group",
     "meta": [
      "4 August 2021"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "FDA",
       "text": "However, upon physical inspection of your facility, the raw data related to your submitted test results were unavailable.",
       "mark": [
        0,
        121
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/bbc-group-limited-614659-08042021",
     "urlLabel": "Read the letter"
    }
   ],
   "note": "47 of 540 letters, newest first after the ones the post quotes"
  },
  {
   "id": "audit-access",
   "label": "Audit trail off, or anyone could change the data",
   "count": 47,
   "records": [
    {
     "title": "Intas Pharmaceuticals",
     "meta": [
      "28 July 2023",
      "21 CFR 211.194(a)"
     ],
     "tags": [
      {
       "label": "Audit trail"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Because the (b)(4) instrument lacked audit trail capabilities, unreported raw data could not be detected during the QA review process.",
       "mark": [
        0,
        134
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/intas-pharmaceuticals-limited-652067-07282023",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Ava",
     "meta": [
      "14 April 2026",
      "21 CFR 211.68(b)"
     ],
     "tags": [
      {
       "label": "Logins and edit rights"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Additionally, analysts had administrator privileges to modify and delete data.",
       "mark": [
        0,
        78
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/ava-inc-721180-04142026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Ultra Seal",
     "meta": [
      "14 March 2022",
      "21 CFR 211.68(b)"
     ],
     "tags": [
      {
       "label": "Logins and edit rights"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Additionally, your analysts have the privileges to modify approved test methods in HPLC equipment.",
       "mark": [
        0,
        98
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/ultra-seal-corporation-624650-03142022",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Medgel",
     "meta": [
      "20 July 2023",
      "21 CFR 211.22"
     ],
     "tags": [
      {
       "label": "Audit trail"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Procedures for review of raw data and audit trails.",
       "mark": [
        0,
        51
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/medgel-private-limited-654085-07202023",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Natural Essentials",
     "meta": [
      "10 November 2026",
      "21 CFR 211.194(a)"
     ],
     "tags": [
      {
       "label": "Logins and edit rights"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "During the inspection, our investigator identified several uncontrolled and unlocked worksheets containing CGMP trending data for the (b)(4) system, leaving the data vulnerable to alteration or deletion.",
       "mark": [
        0,
        203
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/natural-essentials-inc-738543-11102026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Laboratorios Jaloma",
     "meta": [
      "22 May 2026",
      "21 CFR 211.68(b)"
     ],
     "tags": [
      {
       "label": "Audit trail"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your GC laboratory instrument was not adequately qualified because you failed to validate the control software or enable audit trails, and the GC data file creation and modification dates were not accurate.",
       "mark": [
        0,
        206
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/laboratorios-jaloma-sa-de-cv-725939-05222026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "GC America",
     "meta": [
      "14 May 2026",
      "21 CFR 211.68(b)"
     ],
     "tags": [
      {
       "label": "Audit trail"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Furthermore, you were unable to provide audit trails or an SOP describing oversight and retention requirements of electronic records.",
       "mark": [
        0,
        133
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/gc-america-inc-727602-05142026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Intas Pharmaceuticals",
     "meta": [
      "30 March 2026",
      "21 CFR 211.22"
     ],
     "tags": [
      {
       "label": "Audit trail"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your quality assurance employee instructed your software vendor to make changes to your electronic batch record which were not captured in the audit trail or managed through your quality system.",
       "mark": [
        0,
        194
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/intas-pharmaceuticals-limited-721151-03302026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Unipack",
     "meta": [
      "19 December 2025",
      "21 CFR 211.194(a)"
     ],
     "tags": [
      {
       "label": "Audit trail"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "In addition, during a review of system audit trails, our investigator observed multiple \"deleted system\" and \"deleted project\" errors with no assessment report completed as required by your procedure.",
       "mark": [
        13,
        200
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/unipack-llc-716621-12192025",
     "urlLabel": "Read the letter"
    },
    {
     "title": "CDL Services",
     "meta": [
      "24 November 2025",
      "21 CFR 211.68(b)"
     ],
     "tags": [
      {
       "label": "Logins and edit rights"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Establishment of appropriate controls over computer or related systems t o assure that only authorized personnel institute changes in master production and control records or other records (21 CFR 211.68(b)).",
       "mark": [
        87,
        207
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/cdl-services-inc-dba-technichem-713877-11242025",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Taizhou Kangping Medical Science and Technology",
     "meta": [
      "9 October 2025",
      "21 CFR 211.160(b)"
     ],
     "tags": [
      {
       "label": "Logins and edit rights"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Specifically, Excel worksheets used to perform chromatogram calculations were not retained, and access accounts to the GC and HPLC workstations were shared by job title and were not attributable to the individual analyst.",
       "mark": [
        96,
        221
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/taizhou-kangping-medical-science-and-technology-co-ltd-711081-10092025",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Guangxi Yulin Pharmaceutical Group",
     "meta": [
      "30 September 2025",
      "21 CFR 211.68(b)"
     ],
     "tags": [
      {
       "label": "Logins and edit rights"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "For example, your ultraviolet-visible (UV-vis) and infrared (IR) spectroscopy equipment was found to lack audit-trail functionality, and your analysts were able to alter and delete data, files, and folders.",
       "mark": [
        137,
        205
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/guangxi-yulin-pharmaceutical-group-co-ltd-710422-09302025",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Persōn & Covey",
     "meta": [
      "23 September 2025",
      "21 CFR 211.22"
     ],
     "tags": [
      {
       "label": "Audit trail"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Also, audit trails are not independently reviewed after analysis or at an established frequency; and there is no review of the electronic raw data or printed hard copy data.",
       "mark": [
        0,
        95
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/person-covey-inc-711191-09232025",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Wisconsin Pharmacal Company",
     "meta": [
      "22 August 2025",
      "21 CFR 211.68(b)"
     ],
     "tags": [
      {
       "label": "Audit trail"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "During the review of analytical system audit trails for final release testing of finished OTC drug products, our inspection found that your firm does not review audit trails and raw analytical data captured by these analytical instruments.",
       "mark": [
        109,
        239
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/wisconsin-pharmacal-company-llc-710329-08222025",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Shiva Analyticals",
     "meta": [
      "23 July 2025",
      "21 CFR 211.22(d)"
     ],
     "tags": [
      {
       "label": "Logins and edit rights"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Additionally, during the evaluation of audit trail review for your MassLynx software, our investigator documented that your laboratory analysts performed hundreds of entries related to \"Add/Modify/Delete peaks,\" and \"Alter existing file on disk\" user privileges between January 16, 2022, and January 23, 2025.",
       "mark": [
        119,
        309
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/shiva-analyticals-private-limited-707857-07232025",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Evi Labs",
     "meta": [
      "14 May 2025",
      "21 CFR 211.68(b)"
     ],
     "tags": [
      {
       "label": "Logins and edit rights"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Ensure appropriate controls over computer or related systems to assure that only authorized personnel institute changes in master production and control records, or other records (21 CFR 211.68(b)).",
       "mark": [
        0,
        178
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/evi-labs-llc-705846-05142025",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Cosco International",
     "meta": [
      "14 April 2025",
      "21 CFR 211.68(b)"
     ],
     "tags": [
      {
       "label": "Logins and edit rights"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Establishment of appropriate controls of computerized records and access permissions for authorized personnel (21 CFR 211.68(b)).",
       "mark": [
        0,
        129
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/cosco-international-inc-701209-04142025",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Dyno Manufacturing",
     "meta": [
      "9 April 2025",
      "21 CFR 211.68(b)"
     ],
     "tags": [
      {
       "label": "Logins and edit rights"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Appropriate controls over computer or related systems to assu re that only authorized personnel institute changes in master production and control records, or other records as required by 21 CFR 211.68(b).",
       "mark": [
        70,
        204
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/dyno-manufacturing-inc-700785-04092025",
     "urlLabel": "Read the letter"
    },
    {
     "title": "NWL Netherlands Services",
     "meta": [
      "1 April 2025",
      "21 CFR 211.68(b)"
     ],
     "tags": [
      {
       "label": "Logins and edit rights"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "For example, you did not establish unique usernames and passwords, and laboratory staff had administrator rights allowing uncontrolled access to delete or modify high performance liquid chromatography (HPLC), gas chromatography (GC), and fourier transform infrared spectroscopy (FTIR) files.",
       "mark": [
        13,
        65
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/nwl-netherlands-services-bv-701206-04012025",
     "urlLabel": "Read the letter"
    },
    {
     "title": "International Laboratories",
     "meta": [
      "10 March 2025",
      "21 CFR 211.68(b)"
     ],
     "tags": [
      {
       "label": "Logins and edit rights"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Additionally, your analysts had administrative rights capable of altering and deleting data, files, and folders on your chromatographic systems, including the date and time of tests.",
       "mark": [
        14,
        182
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/international-laboratories-corp-698522-03102025",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Annovex Pharma",
     "meta": [
      "5 March 2025",
      "21 CFR 211.68(b)"
     ],
     "tags": [
      {
       "label": "Logins and edit rights"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to exercise appropriate controls over computer or related systems to assure that only authorized personnel institute changes in master production and control records, or other records (21 CFR 211.68(b)).",
       "mark": [
        0,
        200
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/annovex-pharma-inc-698115-03052025",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Aspen Pharmacare Holdings",
     "meta": [
      "24 February 2025",
      "21 CFR 211.68(b)"
     ],
     "tags": [
      {
       "label": "Audit trail"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your Production and QU did not review electronic raw data and audit trails to ensure data integrity prior to batch release.",
       "mark": [
        0,
        123
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/aspen-pharmacare-holdings-limited-701671-02242025",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Indoco Remedies",
     "meta": [
      "16 December 2024",
      "21 CFR 211.22(a) and 211.22(d)"
     ],
     "tags": [
      {
       "label": "Audit trail"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Approximately 18 instances of \"Stop Flow key was pressed\" The procedures governing chromatography analyses do not require the review of all audit trail data.",
       "mark": [
        58,
        157
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/indoco-remedies-limited-691594-12162024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Unexo Lifesciences",
     "meta": [
      "6 November 2024",
      "21 CFR 211.68(b)"
     ],
     "tags": [
      {
       "label": "Logins and edit rights"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "For example, your QC analyst had the ability to manipulate results, dates, and images of in-house and vendor stamp approvals on component certificate of analyses (COAs) from third-party contract laboratories, including the means to duplicate the stamp approval across multiple COAs for components, such as (b)(4) , lot (b)(4) , lot (b)(4) .",
       "mark": [
        13,
        207
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/unexo-lifesciences-private-limited-688163-11062024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Outin Futures",
     "meta": [
      "25 September 2024",
      "21 CFR 211.68(b)"
     ],
     "tags": [
      {
       "label": "Logins and edit rights"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "In addition, your analysts had administrative rights for the chromatography data system capable of changing and deleting files and disabled audit trails for some of your chromatographic systems.",
       "mark": [
        0,
        194
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/outin-futures-corp-684688-09252024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "MMC Healthcare",
     "meta": [
      "24 September 2024",
      "21 CFR 211.68(b)"
     ],
     "tags": [
      {
       "label": "Audit trail"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your ultraviolet-visible (UV-Vis) spectrophotometer computer system lacked appropriate controls to assure the integrity of electronic test data, such as an audit trail and defined user access levels.",
       "mark": [
        0,
        199
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/mmc-healthcare-ltd-684644-09242024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Central Admixture Pharmacy Services",
     "meta": [
      "10 July 2024"
     ],
     "tags": [
      {
       "label": "Audit trail"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Additionally, you stated that \"CAPS aims to be conducting full GxP audit trail reviews by December 31, 2023.\" However, you did not provide an updated procedure or documentation of audit trail reviews in your response.",
       "mark": [
        110,
        217
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/central-admixture-pharmacy-services-inc-687936-07102024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Laboratorio Magnachem International",
     "meta": [
      "18 June 2024",
      "21 CFR 211.68(b)"
     ],
     "tags": [
      {
       "label": "Audit trail"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "You had no mechanism to facilitate traceability of individuals who deleted or modified data generated by computerized systems.",
       "mark": [
        0,
        126
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/laboratorio-magnachem-international-673796-06182024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "GFA Production Xiamen",
     "meta": [
      "13 June 2024",
      "21 CFR 211.194(a)"
     ],
     "tags": [
      {
       "label": "Audit trail"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "This in-house chemical testing was performed without audit trails.",
       "mark": [
        0,
        66
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/gfa-production-xiamen-co-ltd-678364-06132024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Landy International",
     "meta": [
      "12 June 2024",
      "21 CFR 211.68(b)"
     ],
     "tags": [
      {
       "label": "Logins and edit rights"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Additionally, your laboratory personnel used a shared password, located in an unsecured drawer, to access the GC software.",
       "mark": [
        0,
        122
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/landy-international-679066-06122024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Grupo Quimico",
     "meta": [
      "30 April 2024",
      "21 CFR 211.68(b)"
     ],
     "tags": [
      {
       "label": "Audit trail"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Additionally, your HPLC systems \"HPLC 03\" and \"HPLC 04\" did not have audit trails enabled.",
       "mark": [
        0,
        90
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/grupo-quimico-srl-674010-04302024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Westwood Laboratories",
     "meta": [
      "17 April 2024",
      "21 CFR 211.160(b)"
     ],
     "tags": [
      {
       "label": "Logins and edit rights"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Appropriate Control over Laboratory You failed to exercise appropriate controls over your high-performance liquid chromatography (HPLC) software system, such as requiring employee-specific logins, appropriate assignment of administrative privileges, and ensuring the audit trails are enabled.",
       "mark": [
        36,
        248
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/westwood-laboratories-llc-674728-04172024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Central Admixture Pharmacy Services",
     "meta": [
      "25 March 2024",
      "21 CFR 211.68(b)"
     ],
     "tags": [
      {
       "label": "Logins and edit rights"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to exercise appropriate controls over computer or related systems to assure that only authorized personnel institute changes in master production and control records, or other records (21 CFR 211.68(b)).",
       "mark": [
        0,
        220
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/central-admixture-pharmacy-services-inc-675065-03252024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "S & J International Enterprises",
     "meta": [
      "26 January 2024",
      "21 CFR 211.22"
     ],
     "tags": [
      {
       "label": "Logins and edit rights"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "For example, production staff are able to alter master batch records, including modifying batch formulations and other parameters or formulations before printing.",
       "mark": [
        13,
        162
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/s-j-international-enterprises-public-company-limited-668482-01262024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "QuVa Pharma",
     "meta": [
      "26 January 2024",
      "21 CFR 211.68(b)"
     ],
     "tags": [
      {
       "label": "Logins and edit rights"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to exercise appropriate controls over computer or related systems to assure that only authorized personnel institute changes in master production and control records, or other records (21 CFR 211.68(b)).",
       "mark": [
        0,
        220
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/quva-pharma-inc-675685-01262024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Safecor Health",
     "meta": [
      "5 September 2023",
      "21 CFR 211.22"
     ],
     "tags": [
      {
       "label": "Logins and edit rights"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Manufacturing records are not adequately controlled as they can be accessed and printed by employees with access to your firm's (b)(4) site.",
       "mark": [
        0,
        140
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/safecor-health-llc-657886-09052023",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Lex",
     "meta": [
      "17 August 2023",
      "21 CFR 211.68(b)"
     ],
     "tags": [
      {
       "label": "Audit trail"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "You had no mechanism to facilitate traceability of individuals who deleted or modified data generated by computerized systems.",
       "mark": [
        0,
        126
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/lex-inc-656056-08172023",
     "urlLabel": "Read the letter"
    },
    {
     "title": "System Kosmetik Produktionsgesellschaft fur kosmetische",
     "meta": [
      "9 September 2022",
      "21 CFR 211.68(b)"
     ],
     "tags": [
      {
       "label": "Logins and edit rights"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "For example, you did not establish unique usernames and passwords for each analyst.",
       "mark": [
        0,
        83
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/system-kosmetik-produktionsgesellschaft-fur-kosmetische-gmbh-632727-09092022",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Green Wave Analytical",
     "meta": [
      "19 August 2022",
      "21 CFR 211.68(b)"
     ],
     "tags": [
      {
       "label": "Audit trail"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "In addition, the HPLC instrument was found to be operating in the absence of an activated audit trail to record information about each analytical test, such as: • Type of injection • Date and time • Identity of analyst • Nature of action taken and reason You also stated that data from the HPLC was not securely backed up and you did not review the HPLC audit trail data.",
       "mark": [
        326,
        370
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/green-wave-analytical-llc-630965-08192022",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Colorful Products",
     "meta": [
      "10 May 2022",
      "21 CFR 211.68(b)"
     ],
     "tags": [
      {
       "label": "Logins and edit rights"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "You stated to our investigator that these login credentials were shared by multiple employees.",
       "mark": [
        0,
        94
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/colorful-products-corporation-624415-05102022",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Vi-Jon",
     "meta": [
      "31 March 2022",
      "21 CFR 211.68(b)"
     ],
     "tags": [
      {
       "label": "Audit trail"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "The QU reviewed the audit trails only on an (b)(4) basis.",
       "mark": [
        0,
        57
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/vi-jon-llc-622087-03312022",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Accu Bio-Chem Laboratories",
     "meta": [
      "24 February 2022",
      "21 CFR 211.68(b)"
     ],
     "tags": [
      {
       "label": "Logins and edit rights"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "For example, electronic data files generated from your (b)(4) system, used for identity testing of drug products, could be deleted.",
       "mark": [
        0,
        131
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/accu-bio-chem-laboratories-619450-02242022",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Sanitor",
     "meta": [
      "29 November 2021",
      "21 CFR 211.68(b)"
     ],
     "tags": [
      {
       "label": "Logins and edit rights"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Further, you did not have appropriate password protection of your software to prevent unauthorized access to data.",
       "mark": [
        0,
        114
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/sanitor-corporation-616232-11292021",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Missouri Analytical Laboratories",
     "meta": [
      "30 September 2021",
      "21 CFR 211.68(b)"
     ],
     "tags": [
      {
       "label": "Logins and edit rights"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "For example, unique user accounts and privilege levels were not assigned to individual users for (b)(4) software, and the Windows operating system. The analysts had access to delete and overwrite data.",
       "mark": [
        13,
        201
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/missouri-analytical-laboratories-inc-615319-09302021",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Adamson Analytical Laboratories",
     "meta": [
      "17 August 2021",
      "21 CFR 211.68(b)"
     ],
     "tags": [
      {
       "label": "Logins and edit rights"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "During the inspection, our investigators observed that laboratory personnel performing drug analyses had administrative privileges to the (b)(4) operating software for the GC equipment.",
       "mark": [
        23,
        184
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/adamson-analytical-laboratories-inc-614644-08172021",
     "urlLabel": "Read the letter"
    },
    {
     "title": "BBC Group",
     "meta": [
      "4 August 2021",
      "21 CFR 211.68(b)"
     ],
     "tags": [
      {
       "label": "Audit trail"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "In addition, audit trails on your GC were not enabled.",
       "mark": [
        0,
        54
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/bbc-group-limited-614659-08042021",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Allay Pharmaceuticals",
     "meta": [
      "27 January 2021",
      "21 CFR 211.22"
     ],
     "tags": [
      {
       "label": "Audit trail"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Also, you did not perform an assessment to determine the risk from failing to have audit trail enabled controls and unique user passwords.",
       "mark": [
        0,
        138
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/allay-pharmaceuticals-llc-609023-01272021",
     "urlLabel": "Read the letter"
    }
   ],
   "note": "47 of 540 letters, newest first after the ones the post quotes"
  }
 ],
 "download": "Every card is in the {json}, and every finding is in the CSV below."
}
